Vaccines and Global Health: The Week in Review
1 May 2021 :: Issue 605
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at https://centerforvaccineethicsandpolicy.net. This blog allows full text searching of over 21,000 entries.

Comments and suggestions should be directed to
David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

Contents [click on link below to move to associated content]
A. Milestones :: Perspectives :: Featured Journal Content
B. Emergencies
C. WHO; CDC [U.S., Africa, China]
D. Announcements
E. Journal Watch
F. Media Watch
**Editor’s Note:**
As is obvious to all, the sheer volume of strategic announcements, regulatory actions, country program decisions, commentary, and, indeed, misinformation around COVID response continues at extraordinary levels. Our weekly digest strives to present a coherent and comprehensive snapshot, but cannot be exhaustive. If you recognize a missed strategic development, a new source of rigorous analysis, or an insight/commentary that would benefit our common understanding, please advise me...we will review suggestions and consider inclusion in a subsequent edition: david.r.curry@ge2p2global.org

---

**Pandemic Preparedness**

**New global partnership launched to fight future pandemics**

The Government will launch a new Pandemic Preparedness Partnership (PPP) to save lives from future diseases and prevent another global pandemic.

Updated: 20 April 2021

:: *International Pandemic Preparedness Partnership (PPP)* will support PM’s target to slash the time to develop vaccines for new diseases to 100 days

:: Partnership will be chaired by UK Chief Scientific Adviser Sir Patrick Vallance and will report to leaders at June’s G7 Summit

:: New £16m funding to Coalition for Epidemic Preparedness Innovations (CEPI) will also support global vaccine supply and development

The U.K. Government launched a new Pandemic Preparedness Partnership (PPP) to save lives from future diseases and prevent another global pandemic.

The **PPP will advise the UK G7 Presidency on how to meet the Prime Minister’s ambition to slash the time to develop and deploy high quality vaccines for new diseases from 300 to 100 days**, backed by additional funding to support CEPI’s work on global vaccine supply. It will be chaired by the Government’s Chief Scientific Adviser Sir Patrick Vallance.

The public-private partnership will bring together industry, international organisations and leading experts. They will provide recommendations for delivering ambitious targets to more quickly develop vaccines, therapeutics and diagnostics through greater global co-operation on research and development, manufacturing, clinical trials and data-sharing.

The £16 million investment will fund global vaccine manufacturing capacity and critical research and development to rapidly respond to the threat of new strains, supporting the development of new variant-specific vaccines. CEPI’s work to coordinate research, development and manufacturing of vaccines will aid efforts to have millions of doses of vaccine available for emergency use 100 days from a variant of concern being identified.
The PPP is meeting formally for the first time today at a two day virtual Pandemic Preparedness Partnership Conference, taking place under the UK’s Presidency of the G7...

...There 20 members of the PPP include WHO Vaccines Envoy Sir Andrew Witty, Professor of Medicine at the University of Oxford & member of the Bill & Melinda Gates Foundation Scientific Advisory Committee, Sir John Bell, Managing Director of the COVAX Facility Gavi, Aurelia Nguyen, and Chief Executive Officer of the Coalition for Epidemic Preparedness Innovations (CEPI) Richard Hatchett.

Industry members include representatives from leading vaccine developers and life sciences companies such as Head of Global Drug Development and Chief Medical Officer at Novartis, John Tsai, Executive Vice President Biopharmaceuticals R&D at AstraZeneca, Sir Mene Pangalos, Chief Scientific Officer at Pfizer, Mikael Dolsten and Chief Scientific Officer at Johnsen & Johnsen, Paul Stoffels.

These experts will be joined by scientific advisers from our G7 partners, who will play a key role in shaping the recommendations into an actionable roadmap over the next two months through a series of meetings ahead of the June Leader’s Summit...

**Full list of PPP Steering Group members:**

Chair - **Sir Patrick Vallance** - UK Government Chief Scientific Adviser  
**Sir Andrew Witty** – CEO, United Health Group  
**Sir John Bell** - Regius Professor of Medicine, University of Oxford and member of the Bill & Melinda Gates Foundation Scientific Advisory Committee  
**Martin Landray** - Professor of Medicine and Epidemiology, University of Oxford.  
**Dame Anne Johnson** - Professor of Infectious Disease Epidemiology UCL  
**Lord Jim O’Neill** - Former Chairman of Goldman Sachs Asset Management & Former Commercial Secretary to the Treasury  
**Baroness Minouche Shafik** - Director LSE and former Deputy Governor of the Bank of England  
Aurelia Nguyen - Managing Director Office of the COVAX Facility, Gavi  
**Sir Jeremy Farrar** - Director Wellcome Trust & Chair of the Scientific Advisory Group of the WHO R&D Blueprint.  
**Peter Sands** - Executive Director - Global Fund  
**Richard Hatchett** - Chief Executive Officer CEPI  
**Sergio Carmona** - Acting Chief Executive Officer and Chief Medical Officer FIND  
**Soumya Swaminathan** - Chief Scientist WHO  
**John Tsai** - Head of Global Drug Development and Chief Medical Officer, Novartis  
**Sir Mene Pangalos** - Executive Vice President Biopharmaceuticals R&D, AstraZeneca  
**Mikael Dolsten** - Chief Scientific Officer, Pfizer  
**Paul Stoffels** - Vice Chairman and Chief Scientific Officer, J&J  
**Roger Connor** - President Global Vaccines, GSK  
**June Raine** - Chief Executive, MHRA
**Immunization Agenda 2030 [IA 2030] Launch**

**Immunization services begin slow recovery from COVID-19 disruptions, though millions of children remain at risk from deadly diseases -- WHO, UNICEF, Gavi**

*Ambitious new global strategy aims to save over 50 million lives through vaccination*

**GENEVA/NEW YORK, 26 April 2021 ---** While immunization services have started to recover from disruptions caused by COVID-19, millions of children remain vulnerable to deadly diseases, the World Health Organization (WHO), UNICEF and Gavi, the Vaccine Alliance warned today during World Immunization Week, highlighting the urgent need for a renewed global commitment to improve vaccination access and uptake.

"Vaccines will help us end the COVID-19 pandemic but only if we ensure fair access for all countries, and build strong systems to deliver them," said Dr Tedros Adhanom Ghebreyesus, WHO’s Director-General. “And if we’re to avoid multiple outbreaks of life-threatening diseases like measles, yellow fever and diphtheria, we must ensure routine vaccination services are protected in every country in the world."

A WHO survey has found that, despite progress when compared to the situation in 2020, more than one third of respondent countries (37%) still report experiencing disruptions to their routine immunization services.

**Mass immunization campaigns are also disrupted. According to new data, 60 of these lifesaving campaigns are currently postponed in 50 countries, putting around 228 million people - mostly children - at risk for diseases such as measles, yellow fever and polio. Over half of the 50 affected countries are in Africa, highlighting protracted inequities in people’s access to critical immunization services.**

Campaigns to immunize against measles, which is one of the most contagious diseases and can result in large outbreaks wherever people are unvaccinated, are the most impacted. Measles campaigns account for 23 of the postponed campaigns, affecting an estimated 140 million people. Many have now been delayed for over a year.

“Even before the pandemic, there were worrying signs that we were beginning to lose ground in the fight against preventable child illness, with 20 million children already missing out on critical vaccinations,” said Henrietta Fore, UNICEF Executive Director. “The pandemic has made a bad situation worse, causing millions more children to go unimmunized. Now that vaccines are at the forefront of everyone’s minds, we must sustain this energy to help every child catch up on their measles, polio and other vaccines. We have no time to waste. Lost ground means lost lives.”

As a result of gaps in vaccination coverage, serious measles outbreaks have recently been reported in countries including the Democratic Republic of the Congo, Pakistan and Yemen, while likely to occur elsewhere as growing numbers of children miss out on lifesaving vaccines, the agencies warn. These outbreaks are happening in places already grappling with conflict situations as well as service disruptions due to ongoing response measures to COVID-19.

The supply of vaccines and other equipment is also essential for child vaccinations. Due to disruptions at the onset of the COVID-19 pandemic, UNICEF delivered 2.01 billion vaccine doses in 2020, compared to 2.29 billion in 2019.
“Millions of children across the world are likely to miss out on basic vaccines as the current pandemic threatens to unravel two decades of progress in routine immunization”, said Dr Berkley, CEO of Gavi, the Vaccine Alliance. “To support the recovery from COVID-19 and to fight future pandemics, we will need to ensure routine immunization is prioritized as we also focus on reaching children who do not receive any routine vaccines, or zero-dose children. To do this, we need to work together – across development agencies, governments and civil society – to ensure that no child is left behind”.

New global immunization strategy aims to save over 50 million lives
To help tackle these challenges and support the recovery from the COVID-19 pandemic, WHO UNICEF, Gavi and other partners today launched the Immunization Agenda 2030 (IA2030), an ambitious new global strategy to maximize the lifesaving impact of vaccines through stronger immunization systems.

The Agenda focuses on vaccination throughout life, from infancy through to adolescence and older age. If fully implemented, it will avert an estimated 50 million deaths, according to WHO - 75% of them in low- and lower-middle income countries.

Targets to be achieved by 2030 include:
:: Achieve 90% coverage for essential vaccines given in childhood and adolescence[i]
:: Halve the number of children completely missing out on vaccines
:: Complete 500 national or subnational introductions of new or under-utilized vaccines - such as those for COVID-19, rotavirus, or human papillomavirus (HPV)

Urgent action needed from all immunization stakeholders
To achieve IA2030’s ambitious goals, WHO, UNICEF, Gavi and partners are calling for bold action:
:: World leaders and the global health and development community should make explicit commitments to IA2030 and invest in stronger immunization systems, with tailored approaches for fragile and conflict-affected countries. Immunization is a vital element of an effective health care system, central to pandemic preparedness and response, and key to preventing the burden of multiple epidemics as societies reopen
:: All countries should develop and implement ambitious national immunization plans that align with the IA2030 framework, and increase investments to make immunization services accessible to all
:: Donors and governments should increase investments in vaccine research and innovation, development, and delivery, focused on the needs of underserved populations
:: The pharmaceutical industry and scientists, working with governments and funders, should continue to accelerate vaccine R&D, ensure a continuous supply of affordable vaccines to meet global needs, and apply lessons from COVID-19 to other diseases

UNICEF Executive Director Henrietta Fore’s remarks at the special press briefing with WHO and Gavi on the impact of COVID-19 on immunization
As prepared for delivery
NEW YORK, 26 April 2021 – “This week is World Immunization Week. But effectively, this year has become World Immunization Year.
“Because after a year of lockdowns, empty classrooms, missed vaccinations, virtual birthday parties, and cancelled family dinners, people all over the world are now getting a COVID-19 vaccine or anxiously awaiting the moment when they will.

“Those of us in global development understand how important vaccines are. But this year, every single person on the planet knows it.

“Whether you’ve just had a tearful reunion with loved ones for the first time in over a year. Or you’re anxiously awaiting the moment when your turn will come. This year, more than any other, has reminded us that vaccines bring us together.

“But while COVID-19 vaccines represent our best hope of returning to “normal” lives, we need to remind ourselves that millions of children all over the world have no access to vaccines for any preventable diseases whatsoever. This is not a ‘normal’ to which we should return.

“Even before the pandemic, we were losing ground in the fight against preventable child illness. 20 million children were already missing out on critical vaccinations.

“And now, a year into the COVID-19 pandemic, we are still making up lost ground. While there has been progress from the peak of the global lockdowns, routine immunization services remained disrupted in 37 per cent of responding countries in the first quarter of 2021.

“Disruptions as a result of COVID-19 have made this problem worse.

“In 2020, UNICEF, the largest global procurer and supplier of vaccines, delivered 2.01 billion vaccine doses, down from 2.29 billion doses the previous year. Considering the unprecedented global lockdowns and their impact on supply delivery, this was a remarkable achievement.

“UNICEF also managed to deliver 912.7 million syringes for immunization and 10 million safety boxes to 83 countries. And we installed 18,340 cold fridges in health facilities in 25 countries. Another remarkable achievement.

“Over the past few months, we have repeatedly expressed our deep concern about the inequitable distribution of COVID-19 vaccines. WHO said last week that of the over 890 million COVID-19 vaccine doses that have been administered globally, more than 81 per cent have been given in high- and upper-middle-income countries.

“This is not only unfair — it is also unwise, because a threat anywhere is a threat everywhere, especially with the worrying rise in variants.

“But for the people living in the countries where 20 million children are already missing out on life-saving vaccines, it is also unsurprising. Vaccines have always been inequitably distributed.

“Now is the time to change this. We can use this unique moment in time to spur long-term momentum towards finally achieving universal access to routine immunizations and broader primary health care.
“That’s why I am pleased to join my fellow panellists in launching Immunization Agenda 2030 – a comprehensive plan to maximize the impact of vaccination over the next decade.

“IA2030 is an ambitious global strategy to maximize the impact of vaccines. We’re aiming to save an estimated 50 million lives...to halve the number of children receiving zero vaccine doses...and to achieve 90% coverage for key vaccines over the next decade.

“As part of our engagement in IA2030 and World Immunization Week, UNICEF is calling on governments to prioritize strengthening health systems in the poorest countries.

“We need to increase global and domestic investment to continue delivering vaccinations and other critical services for the most vulnerable children, and to guarantee universal, accessible and quality care for the long run.

“We call on governments to protect aid budgets and fulfil existing commitments, which support lifesaving child health services including routine immunization, nutrition and maternal health. Donors should also increase investments in vaccine research and innovation, development, and delivery, focusing on the needs of the underserved.

“The pharmaceutical industry and scientists, working with governments and funders, should continue to accelerate vaccine research and development, ensure a continuous supply of affordable vaccines to meet global needs, and apply lessons from COVID-19 to other diseases.

“Finally, we need to take steps to make sure parents and caregivers trust health workers and heed their advice on vaccinating their children against preventable diseases.

“Later this week, UNICEF will be joining the Yale Institute for Global Health and Public Good Projects to announce a new initiative to equip country teams with tools to counter misinformation and mistrust related to all vaccines. We will be sure to make those details available soon.

“The stage is set for 2021 to be a pivotal year for immunization. Through COVAX and other global efforts to make COVID-19 vaccines available for all, we are embarking on an unprecedented global immunization campaign. But this campaign cannot come at the cost of childhood vaccinations. We cannot trade one global health crisis for another.

“In a year when vaccines are at the forefront of everyone’s minds, we must sustain this energy to accelerate efforts on all three fronts – providing equitable access to COVID-19 vaccines, catching up on missed vaccinations due to pandemic lockdowns, and critically, extending immunization efforts to all children currently missing out on vaccines entirely.

“We have no time to waste. Lost ground means lost lives. Thank you.”
COVID – “Vaccination Financing”

Editor’s Note:
In one of more unusual WHO documents generated in the pandemic context, we note the “Departmental News” item below which has no authors identified and no further attribution. We limited our excerpt to the first “question & answer” – extraordinary for its proscriptive closing point.

WHO :: COVID-19 Vaccination Financing and Budgeting Q&A
27 April 2021  Departmental news
[Excerpt from 10 questions & answers]

What is the overall recommendation with regards to financing?
:: The evolution of the COVID-19 pandemic has demonstrated the unpredictable nature of the virus, with new variants shifting the epicenter of the disease and countries experiencing multiple waves of infections and economic impact. Achieving high vaccination coverage in all countries is the only way to disrupt the pandemic globally and win the race against the virus.

:: The substantial impact that COVID-19 has had on the health and wellbeing of everyone plus its crippling effect on economies across the world means that COVID-19 vaccination will serve two critical functions: an essential health intervention (reducing mortality and morbidity) plus much-needed economic stimulus (allowing economies to re-open). Vaccination can also become a public good: once a critical mass of people have been vaccinated, the herd immunity that results is enjoyed by all.

:: It should follow, then, that financing COVID-19 vaccination is a government-wide responsibility and that governments need to explore how best it should be financed. The very large positive externalities (i.e., the health and economic benefits of vaccination are both at the individual and societal level) arising.

:: Sources of funding for COVID-19 vaccination should not come at the expense of other essential health or social services keeping in mind that said funding, because of its very large positive externalities, is an overall economic decision taken by government and is certainly not limited by the reprogramming of existing MOH budgets. In the case that existing funds are reprogrammed to COVID-19 vaccination from other activities or investments (at the government-wide level), priority should be given to identifying areas of non-productive spending or non-essential activities that can be delayed without negatively impacting population welfare....

COVID Vaccines – OCHA:: HDX

COVID-19 Data Explorer: Global Humanitarian Operations
COVID-19 Vaccine Roll-out
Apr 30, 2021 | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | DATA
Global COVID-19 Figures: 149M total confirmed cases; 3.1M total confirmed deaths
Global vaccines administered: 1.09B
Number of Countries: 26
COVAX First Allocations (Number of Doses): 73M
Weekly Epidemiological and Operational updates
Last update: 1 May 2021

Confirmed cases :: 150,989,419 [week ago: 145,216,414]
Confirmed deaths :: 3,173,576 [week ago: 3,079,390]
Vaccine doses administered: 1,011,457,859

Weekly operational update on COVID-19 - 26 April 2021

Overview
In this edition of the Weekly Operational Update on COVID-19, highlights of country-level actions and WHO support to Member States include:

:: The delivery of COVID-19 vaccine doses to the Syrian Arab Republic via the COVAX Facility
:: Delivery of life-saving oxygen concentrators to the Philippines
:: A joint technical support mission to Albania
:: One year of the pandemic learning response: benefits and performance of the OpenWHO platform during the pandemic
:: Empowering populations to address the COVID-19 infodemic globally and the Africa Infodemic Response Alliance launch of Viral Facts Africa
:: The Strategic Preparedness and Response Plan (SPRP) 2021 resource requirements and progress made to continue investing in the COVID-19 response and for building the architecture to prepare for, prevent and mitigate future health emergencies
:: Updates on WHO/PAHO procured items, Partners Platform, implementation of the Unity Studies, and select indicators from the COVID-19 Monitoring and Evaluation Framework

Weekly epidemiological update on COVID-19 - 27 April 2021

Overview
Globally, new COVID-19 cases increased for the ninth consecutive week, with nearly 5.7 million new cases reported in the last week – surpassing previous peaks. The number of new deaths increased for the sixth consecutive week, with over 87,000 new deaths reported.

In this edition, a special focus update is provided on SARS-CoV-2 variants.
<table>
<thead>
<tr>
<th>Clade</th>
<th>Nextstrain name</th>
<th>Pango lineage</th>
<th>GISAID clade</th>
<th>Alternate name</th>
<th>First detected in</th>
<th>Earliest samples</th>
<th>Characteristic spike mutations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>VOC</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>alias P.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>B.1.429</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20B/S.484K</td>
<td></td>
<td>B.1.1.28.2,</td>
<td>GR</td>
<td></td>
<td>Apr 2020</td>
<td>E484K, D614G, V1176F</td>
<td></td>
</tr>
<tr>
<td></td>
<td>alias P.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>alias P.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20C</td>
<td></td>
<td>B.1.526 with</td>
<td>GH</td>
<td></td>
<td>Nov 2020</td>
<td>L5F, T95I, D253G, D614G, A701V, E484K or S477N</td>
<td></td>
</tr>
<tr>
<td></td>
<td>E484K or S477N</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*While work is ongoing to establish standardized nomenclature for key variants, these are the names by which WHO will refer to them in this publication.*
WHO – COVID Vaccines EUAL, Prequalification, SAGE Meetings/Recommendations

Extraordinary meeting of the Strategic Advisory Group of Experts on Immunization (SAGE) – 29 April 2021
Draft Agenda [Evidence Review/Recommendations: Sinopharm [IBP-CoV] and SinoVac [CoronaVac]]

Draft landscape and tracker of COVID-19 candidate vaccines
30 April 2021 | Publication
The COVID-19 candidate vaccine landscape and tracker database compiles detailed information on COVID-19 vaccine candidates in development.
The landscape is updated regularly - twice a week (Tuesday and Friday, 17:00 CET).
### Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process  23 April 2021

For 19 vaccine candidates, presents Manufacturer, Name of Vaccine, NRA of Record, Platform, EOI Accepted Status, Pre-submission Meeting Held Status, Dossier Accepted for Review, Status of Assessment; Anticipated/Completed Decision Date  
[click on the link above for full scale view]

<table>
<thead>
<tr>
<th>Manufacturer</th>
<th>Name of Vaccine</th>
<th>NRA of Record</th>
<th>Platform</th>
<th>EOI accepted</th>
<th>Pre-submission meeting held</th>
<th>Dossier accepted for review*</th>
<th>Status of assessment**</th>
<th>Anticipated decision date***</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. BioNTech</td>
<td>BNT162b2/COMIRNATY</td>
<td>Takeda (Japan)</td>
<td>mRNA</td>
<td>✔️</td>
<td>✔️</td>
<td>✔️</td>
<td>Finalized</td>
<td>11/12/20</td>
</tr>
<tr>
<td>2. EU Node</td>
<td>AZD1222</td>
<td>GSK – EMA Nanovax</td>
<td>Recombinant (mRNA) adenoviral vector encoding the SARS-CoV-2 Spike protein</td>
<td>✔️</td>
<td>✔️</td>
<td>Accepted core data of AZ – no CRV</td>
<td>Finalized</td>
<td>16 Apr 2021</td>
</tr>
<tr>
<td>3. SinoBiotech</td>
<td>AZD1222</td>
<td>MedPharm Korea</td>
<td>Recombinant (mRNA) adenoviral vector encoding the SARS-CoV-2 Spike protein</td>
<td>✔️</td>
<td>✔️</td>
<td>Finalized</td>
<td>16 Apr 2021</td>
<td></td>
</tr>
<tr>
<td>4. Secure Institute of India</td>
<td>CovShield</td>
<td>SII</td>
<td>Recombinant (Adenovirus) vector encoding the SARS-CoV-2 Spike protein</td>
<td>✔️</td>
<td>✔️</td>
<td>Finalized</td>
<td>15 May 2021</td>
<td></td>
</tr>
<tr>
<td>5. Moderna</td>
<td>mRNA-1273</td>
<td>EMA</td>
<td>mRNA-based vaccine encapsulated in lipid nanoparticles (LNP)</td>
<td>✔️</td>
<td>✔️</td>
<td>Additional data awaited</td>
<td>To be filed after data submission</td>
<td>12 Mar 2021</td>
</tr>
<tr>
<td>6. Sinovac</td>
<td>SARS-CoV-2 Vaccine (Phase 1)</td>
<td>NAVPA</td>
<td>Investigated, produced in vero cells</td>
<td>✔️</td>
<td>✔️</td>
<td>In progress</td>
<td>3rd Apr 2021</td>
<td></td>
</tr>
<tr>
<td>7. Sinovac</td>
<td>SARS-CoV-2 Vaccine (Phase 2)</td>
<td>NAVPA</td>
<td>Investigated, produced in vero cells</td>
<td>✔️</td>
<td>In progress</td>
<td>Early May 2021</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8. AstraZeneca</td>
<td>Ad5-nCoV</td>
<td>NAVPA</td>
<td>Recombinant viral vector vaccine</td>
<td>✔️</td>
<td>✔️</td>
<td>Rolling data starting April 2021</td>
<td>3rd May 2021</td>
<td></td>
</tr>
<tr>
<td>9. Vector State Research Centre of Virology and Biotechnology</td>
<td>LVAXCorona</td>
<td>Russian NRA</td>
<td>Peptide antigen</td>
<td>✔️</td>
<td>Rolling data starting May 2021</td>
<td>3rd May 2021</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12. BioEcoVax, India</td>
<td>Soberana 02</td>
<td>Cuban Ministry of Health</td>
<td>SARS-CoV-2 Spike protein conjugated chemically to lipoprotein (L) or aluminum</td>
<td>✔️</td>
<td>Rolling data starting May 2021</td>
<td>3rd May 2021</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13. Curevac (Bayer AG – Germany)</td>
<td>Curevac COVID-19</td>
<td>EMA</td>
<td>mRNA-based vaccine encapsulated in lipid nanoparticles (LNP)</td>
<td>✔️</td>
<td>Rolling data starting May 2021</td>
<td>3rd May 2021</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Dossier Submission Date: more than one date is provided because of the rolling submission approach. dossier is reviewed after submission of second submission.
*** Anticipated decision date: this is only an estimate because it depends on when all the data is submitted under rolling submission and when all the responses to the assessors’ questions are submitted.

---

### COVID Vaccine Developer/Manufacturer Announcements  [organizations from WHO EUL/PQ listing above]

**AstraZeneca**  
*Press Releases* - No new digest announcements identified

**Bharat Biotech, India**  
*Press Releases* - No new digest announcements identified
BioCubaFarma – Cuba
Últimas Noticias - No new digest announcements identified

CanSinoBIO
News - No new digest announcements identified

Clover Biopharmaceuticals - China
News - No new digest announcements identified

Curevac [Bayer Ag – Germany]
News - No new digest announcements identified

Gamaleya National Center
Latest News and Events - No new digest announcements identified [See Russia/RFID below]

IMBCAMS, China
Home - No new digest announcements identified

Janssen/JNJ
Press Releases
Apr 29, 2021 United States
Fraudulent Advertising for COVID-19 Vaccines: How to Identify Common Scams

Moderna
Press Releases
April 30, 2021
Moderna Announces Emergency Use Listing Granted by the World Health Organization for its COVID-19 Vaccine

April 29, 2021
Moderna Announces Additional Investments to Increase Global Supply for COVID-19 Vaccine to up to 3 Billion Doses in 2022

April 26, 2021
Moderna Announces Agreement with Sanofi for Fill/Finish Manufacturing of the Moderna COVID-19 Vaccine in the U.S.

Novavax
Press Releases - No new digest announcements identified

Pfizer
Recent Press Releases - No new digest announcements identified

Serum Institute of India
NEWS & ANNOUNCEMENTS - No new digest announcements identified

Sinopharm/WIBPBIBP
News - No new digest announcements identified
Sinovac
*Press Releases* - No new digest announcements identified

Vector State Research Centre of Viralogy and Biotechnology
*Home* - No new digest announcements identified

Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
[No website identified]

UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 1 May 2021
An overview of information collected from publicly announced bilateral and multilateral supply agreements [Agreements view from 2021-04-09 to date]

<table>
<thead>
<tr>
<th>Deal date</th>
<th>Recipient</th>
<th>Deal type</th>
<th>Vaccine name</th>
<th>Vaccine developer</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021-04-18</td>
<td>Pakistan</td>
<td>Bilateral</td>
<td>CoronaVac</td>
<td>Sinovac</td>
<td>Sinovac</td>
</tr>
<tr>
<td>2021-04-19</td>
<td>Israel</td>
<td>Bilateral</td>
<td>mRNA-1273</td>
<td>Moderna</td>
<td>Moderna</td>
</tr>
<tr>
<td>2021-04-19</td>
<td>Guinea</td>
<td>Bilateral</td>
<td>CoronaVac</td>
<td>Sinovac</td>
<td>Sinovac</td>
</tr>
<tr>
<td>2021-04-20</td>
<td>Brazil</td>
<td>Bilateral</td>
<td>BNT-162</td>
<td>Pfizer/BioNTech</td>
<td>Pfizer/BioNTech</td>
</tr>
<tr>
<td>2021-04-20</td>
<td>Israel</td>
<td>Bilateral</td>
<td>BNT-162</td>
<td>Pfizer/BioNTech</td>
<td>Pfizer/BioNTech</td>
</tr>
<tr>
<td>2021-04-22</td>
<td>Germany</td>
<td>Bilateral</td>
<td>Sputnik V</td>
<td>Gamaleya Research Institute</td>
<td>Gamaleya Research Institute</td>
</tr>
<tr>
<td>2021-04-22</td>
<td>Thailand</td>
<td>Bilateral</td>
<td>BNT-162</td>
<td>Pfizer/BioNTech</td>
<td>Pfizer/BioNTech</td>
</tr>
<tr>
<td>2021-04-23</td>
<td>Canada</td>
<td>Bilateral</td>
<td>BNT-162</td>
<td>Pfizer/BioNTech</td>
<td>Pfizer/BioNTech</td>
</tr>
<tr>
<td>2021-04-23</td>
<td>Canada</td>
<td>Bilateral</td>
<td>BNT-162</td>
<td>Pfizer/BioNTech</td>
<td>Pfizer/BioNTech</td>
</tr>
<tr>
<td>2021-04-23</td>
<td>Canada</td>
<td>Bilateral</td>
<td>BNT-162</td>
<td>Pfizer/BioNTech</td>
<td>Pfizer/BioNTech</td>
</tr>
</tbody>
</table>

*No new agreements reported since last week’s report*
Our World in Data
Coronavirus (COVID-19) Vaccinations

Daily COVID-19 vaccine doses administered per 100 people, Apr 30, 2021
Shown is the rolling 7-day average per 100 people in the total population. This is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses).

Source: Official data collated by Our World in Data – Last updated 1 May, 11:20 (London time) OurWorldInData.org/coronavirus • CC BY
U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Vaccines and Related Biological Products Advisory Committee
No new digest content identified.

Advisory Committee on Immunization Practices (ACIP)
Meeting Draft Agenda – May 5, 2021
:: Rabies Vaccine
:: Dengue Vaccine

White House [U.S.]
Briefing Room – Selected Major COVID Announcements
A Proclamation on the Suspension of Entry as Nonimmigrants of Certain Additional Persons Who Pose a Risk of Transmitting Coronavirus Disease 2019
The Centers for Disease Control and Prevention (CDC), within the Department of Health and Human Services, working in close coordination with the Department of Homeland Security, has determined that the Republic of India is experiencing widespread, ongoing person-to-person transmission of SARS-CoV-2, the virus that causes COVID-19. The World Health Organization has reported that the Republic of India has had more than 18,375,000 confirmed cases of COVID-19. The magnitude and scope of the COVID-19 pandemic in the Republic of India is surging; the Republic of India accounts for over one-third of new global cases, and the number of new cases in the Republic of India is accelerating at a rapid rate. There have been more than 300,000 average new daily cases in the Republic of India over the past week. A variant strain of the virus, known as B.1.617, is also circulating in the Republic of India, along with other variant strains, including B.1.1.7, first detected in the United Kingdom, and B.1.351, first detected in the Republic of South Africa. The CDC advises, based on work by public health and scientific experts, that these variants have characteristics of concern, which may make them more easily transmitted and have the potential for reduced protection afforded by some vaccines.

After reviewing the public health situation within the Republic of India, CDC has concluded that proactive measures are required to protect the Nation's public health from travelers entering the United States from that jurisdiction...

Given the determination of CDC, working in close coordination with the Department of Homeland Security, described above, I have determined that it is in the interests of the United States to take action to restrict and suspend the entry into the United States, as nonimmigrants, of noncitizens of the United States ("noncitizens") who were physically present within the Republic of India during the 14-day period preceding their entry or attempted entry into the United States...
Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

**European Medicines Agency**

*News & Press Releases*

**EMA and ECDC join forces for enhanced post-marketing monitoring of COVID-19 vaccines in Europe**

News 26/04/2021

The European Medicines Agency (EMA) and the European Centre for Disease Prevention and Control (ECDC) today kicked off a new initiative aimed at strengthening post-marketing monitoring of the safety, effectiveness and impact of COVID-19 vaccines in the European Union (EU) and the European economic Area (EEA).

With the ongoing authorisation and rollout of several COVID-19 vaccines in the EU, jointly coordinated, large-scale, EU-wide effectiveness and safety studies are an essential tool to closely monitor how these novel vaccines perform in real life. These studies are key to generate adequate evidence to support continuous assessment of the benefits and risks of the vaccines and inform decision-making on their use in national or regional vaccination strategies for different populations.

EMA and ECDC will jointly coordinate and oversee a number of observational studies which will be funded from the EU budget and conducted in several European countries. In line with their respective mandates and in collaboration with EU/EEA countries, EMA leads on monitoring the safety, and ECDC the effectiveness, of these vaccines. This work will be supported by a Joint Advisory Board (JAB) to the two Agencies that held its first meeting today...

**European Commission**

*Press release 27 April 2021*
Coronavirus: EU channels critical support to India via EU Civil Protection Mechanism
A shipment of urgently needed oxygen, medicine and equipment will be delivered over the coming days by EU Member States to India, following the country's request for support through the EU Civil Protection Mechanism, which is coordinated by the Emergency Response Coordination Centre of the EC.

Statement 26 April 2021

Joint Statement on European Immunization Week 2021: Celebrating the past, present and future benefits of vaccines
Joint Statement on European Immunization Week 2021: Celebrating the past, present and future benefits of vaccines

Africa: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

No new digest content identified.

Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Russia: Sputnik V – "the first registered COVID-19 vaccine"
https://sputnikvaccine.com/newsroom/pressreleases/

Press Releases
The Gamaleya Center statement on a disinformation campaign against Sputnik V vaccine
Press release, 30.04.2021

Sputnik V approved for use in Albania
Press release, 30.04.2021

Turkey becomes the 63rd country in the world to authorize Sputnik V
Press release, 30.04.2021

SPUTNIK V STATEMENT ON BRAZILIAN HEALTH REGULATOR ANVISA’S DECISION TO POSTPONE SPUTNIK V AUTHORIZATION IN BRAZIL:
Press release, 28.04.2021

Sputnik V authorized in Bangladesh
Press release, 27.04.2021

The Gamaleya Center statement on increasing the interval between first and second Sputnik V vaccine shots
Press release, 26.04.2021

RDIF and Viscoran İlaç agree to produce the Sputnik V vaccine in Turkey
India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Government of India – Press Information Bureau

Latest Press Releases
PM reviews Covid related situation in a meeting with Empowered Groups
Posted on: 30 Apr 2021

Prime Minister chairs a high-level meeting to review the Covid-19 related situation in the country
Posted on: 27 Apr 2021

PM Narendra Modi chaired a meeting with top officials to review the Covid-19 relation situation in the country. He got an overview on the situation in the country relating to oxygen availability, medicines, health infrastructure, etc.

Ministry of Health and Family Welfare
https://www.mohfw.gov.in/

COVID-19 INDIA as on : 01 May 2021, 08:00 IST (GMT+5:30)
(1↓ Status change since yesterday)

Active (17.06%) 3268710 (98482↑)
Discharged (81.84%) 15684406 (299988↑)
Deaths (1.11%) 211853 (3523↑)

Latest Updates
29.04.2021 Revised guidelines for Home Isolation of mild /asymptomatic COVID-19 cases

Indian Council for Medical Research (ICMR)
https://www.icmr.gov.in/media.html
No new digest content identified.

China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

[See China CDC section below]
Emergencies

POLIO

Public Health Emergency of International Concern (PHEIC)

Polio this week as of 28 April 2021
:: The GPEI has released a position statement on the use of the novel oral polio vaccine type 2 in light of shelf-life of 12 months or less. The purpose of the statement is to assist governments of countries affected by or at risk of cVDPV2 outbreaks optimize the use of deployed nOPV2 stocks.

Summary of new WPV and cVDPV viruses this week (AFP cases and ES positives):
:: Afghanistan: one cVDPV2 case
:: Pakistan: one WPV1 and three cVDPV2 positive environmental samples
:: DR Congo: one cVDPV2 case
:: Liberia: one cVDPV2 case and two cVDPV2 positive environmental samples
:: Madagascar: three cVDPV1 cases and three cVDPV1 positive environmental samples
:: Mali: one cVDPV2 case
:: Nigeria: two cVDPV2 cases and one cVDPV2 positive environmental sample
:: Sierra Leone: three cVDPV2 cases
:: South Sudan: one cVDPV2 case
:: Tajikistan: one cVDPV2 case

WHO/OCHA Emergencies

Editor’s Note:
Continuing with this edition, we include information about the last apparent update evident on the WHO emergency country webpages, recognizing almost universal and significant interims since last update regardless of the level of the emergency listed.

WHO Grade 3 Emergencies [to 1 May 2021]

Democratic Republic of the Congo - No new digest announcements [Last apparent update: 12 Jan 2021]
Mozambique floods - No new digest announcements identified [Last apparent update: 3 November 2020]
Nigeria - No new digest announcements identified [Last apparent update: 29 Jun 2020]
Somalia - No new digest announcements identified [Last apparent update: 17 July 2020]
South Sudan - No new digest announcements identified [Last apparent update: 4 February 2020]
Syrian Arab Republic - No new digest announcements identified [Last apparent update: 24 October 2020]
Yemen - No new digest announcements identified [Last apparent update: 30 June 2020]
WHO Grade 2 Emergencies [to 1 May 2021]

Iraq
:: World Immunization Week - vaccines bring us closer  28 April 2021

Measles in Europe
:: Getting closer together – one vaccination at a time 26-04-2021

Afghanistan - No new digest announcements identified [Last apparent update: 5 July 2020]
Angola - No new digest announcements identified [Last apparent update: 16 March 2021]
Burkina Faso - No new digest announcements identified [Last apparent update: 01 avril 2021]
Burundi - No new digest announcements identified [Last apparent update: 04 July 2019]
Cameroon - No new digest announcements identified [Last apparent update: 22 August 2019]
Central African Republic - No new digest announcements identified [Last apparent update: 12 June 2018]
Ethiopia - No new digest announcements identified [Last apparent update: 22 August 2019]
Iran floods 2019 - No new digest announcements identified [Last apparent update: 2 March 2020]
Libya - No new digest announcements identified [Last apparent update: 7 October 2019]
Malawi - No new digest announcements identified [Last apparent update: 22 April 2021]
MERS-CoV - No new digest announcements identified [Last apparent update: 8 July 2019]
Mozambique - No new digest announcements identified [Last apparent update: 03 November 2020]
Myanmar - No new digest announcements identified [Last apparent update: 29 March 2021]
Niger - No new digest announcements identified [Last apparent update: 16 avril 2021]
occupied Palestinian territory - No new digest announcements identified [Last apparent update: 4 September 2019]
HIV in Pakistan - No new digest announcements identified [Last apparent update: 27 August 2019]
Sao Tome and Principe Necrotizing Cellulitis (2017) - No new digest announcements
Sudan - No new digest announcements identified [Last apparent update: 24 June 2020]
Ukraine - No new digest announcements identified [Last apparent update: 1 May 2019]
Zimbabwe - No new digest announcements identified [Last apparent update: 10 May 2019]

:::

WHO Grade 1 Emergencies [to 1 May 2021]

Chad - No new digest announcements identified [Last apparent update: 30 June 2018]
Djibouti - No new digest announcements identified [Last apparent update: 25 novembre 2020]
Kenya - No new digest announcements identified [Last apparent update: 23 April 2021]
Mali - No new digest announcements identified [Last apparent update: 3 May 2017]
Namibia - viral hepatitis - No new digest announcements identified [Last apparent update: 20 July 2018]
Tanzania - No new digest announcements identified [Last apparent update: 21 October 2019]

:::

UN OCHA – Current Emergencies
System-wide Scale-up Responses
IASC Humanitarian System-Wide Scale-Up Activations and Deactivations

Published Date: 30 April 2021

Currently active Scale-Ups

northern Ethiopia

- IASC System-Wide Scale-Up Activated on 28 April 2021.

Current Corporate Emergencies

Northern Ethiopia

:: Ethiopia Humanitarian Bulletin Issue #5 29 March – 23 April ...

HIGHLIGHTS

:: As of 25 April, Ethiopia counts 252,279 COVID-19 cases, including 59,979 active cases and 3,551 deaths (1.4 per cent case fatality rate).
:: The test positivity rate stands at 25 per cent, while in cities like Dire Dawa and Hawassa, positivity rate is close to 50 per cent. Despite this alarming development, the population is not showing significant behavior change in implementing COVID-19 prevention measures.
:: The complex and unpredictable security situation in several areas of Tigray Region continues to affect the delivery of full-scale humanitarian assistance to affected communities, particularly to those who live in rural areas.

:::
:::
:::

WHO & Regional Offices [to 1 May 2021]

https://www.who.int/

30 April 2021  Departmental news

Joint Statement: WHO Director-General and the Civil Society Task Force on TB

29 April 2021  Departmental news

Deworming women during pregnancy has a positive effect on child survival and health

29 April 2021  Departmental news

WHO Publishes new guidance to promote Strong, Efficient and Sustainable Regulatory Systems

29 April 2021  Departmental news

NTDs: pulse survey shows COVID-19 continues to disrupt health services

28 April 2021  Departmental news

Governments commit to accelerated action to prevent drowning

27 April 2021  Departmental news

COVID-19 Vaccination Financing and Budgeting Q&A
[See COVID above for detail]

26 April 2021  Departmental news

Leprosy (Hansen’s disease): interrupting transmission and achieving zero autochthonous cases
Tribute to John Storey

Immunization services begin slow recovery from COVID-19 disruptions, though millions of children remain at risk from deadly diseases – WHO, UNICEF, Gavi
[See COVID above for detail]

WHO designates new collaborating centre to support clinical management of leishmaniasis

Weekly Epidemiological Record, Vol. 96, No. 17, pp. 133–144, 30 April 2021
:: Meeting of the Immunization and Vaccine-related Implementation Research Advisory Committee (IVIR-AC), March 2021

WHO Regional Offices
Selected Press Releases, Announcements

WHO African Region AFRO
:: African vaccine champion on lessons from ending wild polio 29 April 2021
   Vaccines save millions of lives each year. In August 2020, Africa crossed a historic milestone when it was certified as free of wild polio. Vaccination drives, reaching up to 220 million African children multiple times every year, were integral to achieving this historic milestone.
:: Emerging lessons from Africa’s COVID-19 vaccine rollout 27 April 2021
   With 47 African countries now rolling out COVID-19 vaccines and over 17 million doses given on the continent, early insights from Africa’s largest-ever immunization drive offer hope, inspiration and early, yet vital lessons. Here, we shine a light on key lessons emerging from countries that have made strong progress, including Angola, Ghana, Mauritius and Rwanda.

WHO Region of the Americas PAHO
No new digest content identified

WHO South-East Asia Region SEARO
:: Address critical gaps urgently: WHO 28 April 2021 News release
:: World Malaria Day 25 April 2021 Statement

WHO European Region EURO
:: More Europeans now vaccinated against COVID-19 than have had the virus 29-04-2021
:: For the common good: patients and health workers tell Regional Director of COVID-19 challenges and hopes for the future during country visit 28-04-2021
:: United action for stronger quality of care in the European Region – WHO supports Greece in building a national health system for the 21st century 27-04-2021
:: This week we celebrate the role of vaccines in bringing us closer 27-04-2021
People in prisons should not be left behind amid COVID-19 vaccination

WHO Eastern Mediterranean Region EMRO
:: World Immunization Week - vaccines bring us closer 28 April 2021
:: Government of Italy/WHO support children with malnutrition in Yemen 28 April 2021
:: Sudan launches yellow fever vaccination campaign 27 April 2021

WHO Western Pacific Region
No new digest content identified

CDC/ACIP [U.S.] [to 1 May 2021]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html
Latest News Releases, Announcements
Fully Vaccinated Adults 65 and Older Are 94% Less Likely to Be Hospitalized with COVID-19
Wednesday, April 28, 2021

MMWR News Synopsis Friday, April 30, 2021
:: COVID-19 Outbreak Among Farmworkers — Okanogan County, Washington, May–August 2020
:: COVID-19 Among Workers in the Seafood Processing Industry: Implications for Prevention Measures — Alaska, March–October 2020
:: Linked Clusters of SARS-CoV-2 Variant B.1.351 — Maryland, January–February 2021
:: Postvaccination SARS-CoV-2 Infections Among Skilled Nursing Facility Residents and Staff Members — Chicago, Illinois, December 2020–March 2021 (Early Release April 21, 2021)
:: COVID-19 Outbreak Associated with a SARS-CoV-2 R.1 Lineage Variant in a Skilled Nursing Facility After Vaccination Program — Kentucky, March 2021 (Early Release April 21, 2021)
:: Updated Recommendations from the Advisory Committee on Immunization Practices for Use of Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021 (Early Release April 27, 2021)

Coronavirus Disease 2019 (COVID-19) - CDC
Selected Resources

4/30/21EARLY RELEASE: Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine - United States, March-April 2021
On April 30, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 16 new cases of confirmed infections.

China continues measures to control imported COVID cases

Updated: 2021-04-30

China will continue to take strict measures to prevent imported COVID-19 infections via people or goods after several inbound travelers tested positive for novel coronavirus after finishing quarantine, a senior health official said on April 29.

Wang Bin, a senior official at the National Health Commission, said the commission requires all inbound travelers to take nucleic acid tests during quarantine.

At the end of the 14-day medical quarantine, they should receive nucleic acid tests from at least two institutions to increase the accuracy of the tests, she said at a news conference.

After they finish the 14-day medical quarantine, they should observe seven-day home health monitoring, take necessary epidemic containment measures when going out and avoid large gatherings, she said...

National Medical Products Administration – PRC [to 1 May 2021]
Vice-premier stresses production, supply of COVID-19 vaccines
2021-04-30
Vice-Premier Sun Chunlan on April 29 called for speeding up the production and supply of COVID-19 vaccines, ensuring quality and safety and promoting vaccination among the public to build an immune barrier.

Over 243 million COVID-19 vaccine doses administered across China
2021-04-30
More than 243.9 million doses of COVID-19 vaccines had been administered across China as of Wednesday, the National Health Commission said on April 29.

China’s new recombinant COVID-19 vaccine starts human tests
2021-04-25
Chinese pharmaceutical giant Sinopharm has commenced phase-1 and phase-2 clinical trials for its new recombinant vaccine against COVID-19 in Central China’s Henan province since April 24.

Organization Announcements
Editor’s Note:
Careful readers will note that the number and range of organizations now monitored in our Announcements section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

Paul G. Allen Frontiers Group  [to 1 May 2021]
News
[Website not responding at inquiry]

BARDA – U.S. Department of HHS  [to 1 May 2021]
https://www.phe.gov/about/barda/Pages/default.aspx
News
No new digest content identified.

BMGF - Gates Foundation  [to 1 May 2021]
https://www.gatesfoundation.org/ideas/media-center
Press Releases and Statements
No new digest content identified.

Bill & Melinda Gates Medical Research Institute  [to 1 May 2021]
https://www.gatesmri.org/
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people.
EDCTP [to 1 May 2021]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
25 April 2021
World Malaria Day 2021
On World Malaria Day 2021, EDCTP joins all partners in the ‘Zero Malaria – Draw the Line Against Malaria’ campaign towards the goal of malaria...

Emory Vaccine Center [to 1 May 2021]
http://www.vaccines.emory.edu/
Vaccine Center News
No new digest content identified.

European Vaccine Initiative [to 1 May 2021]
http://www.euvaccine.eu/
Latest News
European Immunization Week 2021
‘Vaccines bring us closer’ across the world, organisations and generations’

FD [to 1 May 2021]
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm
Press Announcements | Selected Details
April 30, 2021 - Coronavirus (COVID-19) Update: April 30, 2021

April 28, 2021 - FDA Takes Action For Failure to Submit Required Clinical Trial Results Information to ClinicalTrials.Gov

April 27, 2021 - Coronavirus (COVID-19) Update: April 27, 2021
:: On April 23, the FDA and Centers for Disease Control and Prevention (CDC) issued a press release lifting the recommended pause on the use of Janssen (Johnson & Johnson) COVID-19 Vaccine following a thorough safety review. The FDA added and updated some questions about resuming the use of this vaccine to the Janssen COVID-19 Frequently Asked Questions webpage

Fondation Merieux [to 1 May 2021]
http://www.fondation-merieux.org/
News, Events
No new digest content identified.
**Gavi** [to 1 May 2021]
https://www.gavi.org/
*News Releases*
26 April 2021
*Immunization services begin slow recovery from COVID-19 disruptions, though millions of children remain at risk from deadly diseases*
[See COVAX above for detail]

**GHIT Fund** [to 1 May 2021]
https://www.ghitfund.org/newsroom/press
*GHIT was set up in 212 with the aim of developing new tools to tackle infectious diseases that No new digest content identified.*

**Global Fund** [to 1 May 2021]
*News & Stories*
*India’s devastating COVID-19 crisis*
30 April 2021
...As part of the Global Fund’s COVID-19 Response Mechanism 2021, we have made available an initial base allocation of US$75 million to support India’s response to COVID-19. We are working closely with the Government of India and national partners to help them access the new emergency funding and identify solutions to the most critical needs.

The Global Fund is also working with international partners to support India. In February 2021, the COVID-19 Oxygen Emergency Taskforce was launched by Unitaid and the Wellcome Trust as co-leaders of the Access to COVID-19 Tools Accelerator (ACT-Accelerator) Therapeutics Pillar, to respond to the surging oxygen emergency in low- and middle-income countries. The taskforce brings together key organizations including Unitaid, the Wellcome Trust, the Global Fund, WHO, Unicef, World Bank, the Clinton Health Access Initiative (CHAI), PATH, the Every Breath Counts coalition and Save the Children...

**Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [to 1 May 2021]
https://www.glopid-r.org/news/
*News*
*No new digest content identified.*

**Hilleman Laboratories** [to 1 May 2021]
http://www.hillemanlabs.org/
*Website not responding at inquiry*

**Human Vaccines Project** [to 1 May 2021]
http://www.humanvaccinesproject.org/media/press-releases/
The document presents a list of questions (a checklist or compatibility study) that cover some of the main challenges related to the protection of health care during armed conflict and other emergencies.

28-04-2021 | Publication

**Without urgent action to protect essential services in conflict zones we face vast humanitarian disaster**

Speech given by Mr Peter Maurer, President of the International Committee of the Red Cross, to the UNSC Open Debate on the Protection of Objects Indispensable to the survival of the civilian population.

27-04-2021 | Statement
**IFRC calls for an urgent scale-up of vaccinations, health interventions and economic support as the pandemic continues to surge in the Americas**

As the Americas region continues to see a surge in COVID-19 cases and deaths, the International Federation of Red Cross and Red Crescent Societies (IFRC) is calling for an urgent scaling up of public health interventions, vaccinations and economic support for the most vulnerable. With almost half of the cases and deaths from COVID-19 in the world, the continent continues to bear the brunt of this monumental crisis on various fronts.

28 April 2021

**India**

**IFRC urges unity to vaccinate the world against COVID-19 as countries unite to help India**

Kuala Lumpur/Delhi/Geneva, 28 April – The terrible toll of death and illness unfolding in India reinforces that this pandemic is far from over. The International Federation of Red Cross and Red Crescent Societies (IFRC) urges the whole world to unify a ...

28 April 2021

**Philippines**

**Philippines: Red Cross eases burden on hospitals under siege as COVID-19 cases hit 1 million**

Kuala Lumpur/Manila, 26 April – Record COVID-19 surges across the Philippines have placed hospitals under siege as total Coronavirus infections pass 1 million. Red Cross is urgently setting up field hospitals, quarantine facilities and scaling up exist ...

26 April 2021

**Institut Pasteur** [to 1 May 2021]


*Press release*

*No new digest content identified.*

**IRC International Rescue Committee** [to 1 May 2021]


*Media highlights [Selected]*

*Press Release*

**NE Syria: As COVID surges, hospitals face acute O2 shortage and testing is in jeopardy; IRC makes urgent call for more funding and support to boost COVID response**

April 27, 2021

**IVAC** [to 1 May 2021]

https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html

*Updates; Events*

*No new digest content identified.*

**IVI** [to 1 May 2021]

http://www.ivi.int/
Selected IVI News, Announcements, Events
No new digest content identified.

**JEE Alliance**  [to 1 May 2021]
https://www.jeealliance.org/
Selected News and Events
No new digest content identified.

**Johns Hopkins Center for Health Security**  [to 1 May 2021]
https://www.centerforhealthsecurity.org/news/center-news/
Center News
No new digest content identified.

**MSF/Médecins Sans Frontières**  [to 1 May 2021]
http://www.msf.org/
Latest [Selected Announcements
Coronavirus COVID-19 pandemic
**Responding to COVID-19: Global Accountability Report 3 - September to December 2020**
Report = 29 Apr 2021
... From March to December 2020, Médecins Sans Frontières (MSF) responded to the pandemic through our existing programmes and dedicated COVID-19 interventions in more than 300 projects in 70 countries. Our global COVID-19 activities focused on delivering medical care and other assistance to vulnerable people at risk of being left behind, including remote communities, people on the move, homeless people, and elderly people living in long-term care facilities...

**National Academy of Medicine** - USA  [to 1 May 2021]
https://nam.edu/programs/
Selected News/Programs
Upcoming Events:
**Collaborating with Communities about COVID-19, Climate, and Community Concerns: A Roundtable Discussion**
May 4, 2021  1:00PM - 2:30PM (ET)

**COVID-19 Vaccines: Building Confidence and Explaining Efficacy, Webinar**
May 4, 2021  3:00PM - 4:00PM (ET)

**National Vaccine Program Office** - U.S. HHS  [to 1 May 2021]
https://www.hhs.gov/vaccines/about/index.html
Upcoming Meetings/Latest Updates
No new digest content identified.

**NIH**  [to 1 May 2021]
NIH to invest $29 million to address COVID-19 disparities

April 29, 2021 — Effort will foster community-engagement research in communities which have been hit hardest by the pandemic.

UN OCHA Office for the Coordination of Humanitarian Affairs [to 1 May 2021]
https://www.unocha.org/
Press Releases
No new digest content identified.

PATH  [to 1 May 2021]
https://www.path.org/media-center/
Press Releases
PATH welcomes Samantha Power as new USAID administrator
April 28, 2021 by PATH

Sabin Vaccine Institute  [to 1 May 2021]
http://www.sabin.org/updates/pressreleases
Statements and Press Releases
No new digest content identified.

UNAIDS [to 1 May 2021]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
30 April 2021
Joint mission supports the response to HIV in Gboklè/Nawa/San Pedro, Côte d'Ivoire
26 April 2021
High rates of hepatitis C and HIV coinfection among key populations
26 April 2021
Interactive multistakeholder hearing takes place ahead of United Nations High-Level Meeting on AIDS

UNDP  United Nations Development Programme [to 1 May 2021]
http://www.undp.org/content/undp/en/home/presscenter.html
Latest from News Centre
Pandemic and political crisis could result in half of Myanmar’s population living in poverty by 2022, UNDP says
   The combined effects of the two crises could put over a decade of progress on poverty reduction in the country at risk.
   Posted on April 30, 2021
UNESCO [to 1 May 2021]
http://en.unesco.org/news
Selected Latest News
No new digest content identified.

UNHCR Office of the United Nations High Commissioner for Refugees [to 1 May 2021]
Selected News Releases, Announcements
No new digest content identified.

UNICEF [to 1 May 2021]
https://www.unicef.org/media/press-releases
Selected Press Releases, Statements
News note
04/29/2021
UNICEF sends 3,000 oxygen concentrators and other critical supplies to India as country battles deadly COVID-19 surge

Press release
04/28/2021
Vaccination Demand Observatory launched to strengthen local communication programmes to address vaccine misinformation
UNICEF, Yale Institute for Global Health, and Public Good Projects team up to create the Vaccination Demand Observatory to equip country teams with tools to counter misinformation and mistrust related to all vaccines
...The Vaccine Acceptance Interventions Lab (VAIL) will draw upon behavioural and social research and insights from social listening to develop engaging, relevant content to fill information gaps. VAIL also will develop “inoculation” messages to vaccinate people against vaccine misinformation. The content and programs will be rapid field tested for tone, format and behavior change impact before being implemented...

Statement
04/26/2021
UNICEF Executive Director Henrietta Fore’s remarks at the special press briefing with WHO and Gavi on the impact of COVID-19 on immunization
As prepared for delivery
[See Milestones above for detail]

Press release
04/26/2021
Immunization services begin slow recovery from COVID-19 disruptions, though millions of children remain at risk from deadly diseases – WHO, UNICEF, Gavi
Ambitious new global strategy aims to save over 50 million lives through vaccination
[See Milestones above for detail]
**Unitaid** [to 1 May 2021]
https://unitaid.org/

*Featured News*

**28 April 2021**

**Unitaid and Wellcome statement regarding MSD’s global access plan for molnupiravir, a potential treatment for COVID-19.**

Geneva – ACT-Accelerator Therapeutics co-leads Wellcome and Unitaid welcome MSD’s commitment to voluntary licensing agreements with five generic manufacturers to serve the needs of India and 100 other low- and middle-income countries (LMICs). This is an important first step to accelerate and expand global access for molnupiravir, should upcoming clinical data prove it safe and effective.

Industry plays a central role in ensuring a rapid and effective COVID-19 response. Their commitment to the development of promising therapeutics for COVID-19 is critical in the race to end the pandemic and in meeting the continued need for treatments for COVID-19.

We also welcome MSD’s engagement with the Unitaid-supported Medicines Patent Pool (MPP) to further broaden access to molnupiravir. In anticipation of a potential approval in the months to come, robust plans for affordable access in all low- and middle-income countries are required, including middle-income countries in Africa, Asia and Latin America, given the trajectory of the pandemic.

**28 April 2021**

**Access to HIV self-tests significantly expanded and costs halved thanks to Unitaid agreement**

:: Self-testing vital tool to help people know HIV status – but market has been dominated by single oral-based self-test
:: New Unitaid-led agreement with Viatris (through its subsidiary Mylan) reduces price of blood-based HIV self-test by 50%, significantly expanding market and giving countries more options
:: New test will be available for less than $2 in 135 countries
:: Self tests key factor in achieving SDG target of 90% of people infected with HIV knowing their status

**27 April 2021**

**ANTICOV: largest clinical trial in Africa for people with mild COVID-19 to test new drug combination**

*Need for effective COVID-19 treatments remains particularly acute, especially in sub-Saharan Africa where access to vaccines is still extremely limited*

Geneva – The ANTICOV clinical trial, conducted in 13 African countries, has started the recruitment of participants to test a new drug combination, nitazoxanide + ciclesonide, to treat people with mild-to-moderate COVID-19 before their cases become severe.

The ANTICOV study is being carried out by a consortium of 26 partners which include leading African research institutions and international health organizations, coordinated by the non-profit research and development (R&D) organization Drugs for Neglected Diseases initiative (DNDi). It is the largest trial in Africa to identify early COVID-19 treatments that can prevent progression to severe disease and potentially limit transmission.

“In many African countries our worst fears are being realised, as already-strained intensive care units are beginning to fill up with COVID-19 patients,” said Dr John Nkengasong, Director of the Africa Centres for Disease Control and Prevention (Africa CDC). “Yet the number of vaccine doses that are reaching the African continent is too limited. The rapid spread of new variants also threatens to reduce
the efficacy of existing vaccines, which is another major cause for concern. We need urgently to identify affordable and easy-to-administer treatments that can prevent the evolution to a severe form of the disease and slow the rate of infection.”

**Vaccination Acceptance Research Network (VARN)** [to 1 May 2021]
https://vaccineacceptance.org/news.html#header1-2r

*Announcements*
*No new digest content identified.*

**Vaccine Confidence Project** [to 1 May 2021]
http://www.vaccineconfidence.org/

*News, Research and Reports*
**Coronavirus global impact**
Launched April 2, 2020 and recurring every 3 days, Premise Data is utilizing its global network of Contributors to assess economic, social, and health sentiment surrounding the coronavirus (COVID-19).

**Vaccine Education Center – Children’s Hospital of Philadelphia** [to 1 May 2021]
http://www.chop.edu/centers-programs/vaccine-education-center

*News*
*No new digest content identified.*

**Wellcome Trust** [to 1 May 2021]
https://wellcome.ac.uk/news

*News and reports*
**Explainer**
**Why we need to share vaccine doses now and why COVAX is the right way to do it**
26 April 2021
We need urgent international action to achieve more equitable global access to Covid-19 vaccines. Countries that have ordered more vaccine doses than they need are best placed to take the lead, by sharing doses now, through COVAX.

**The Wistar Institute** [to 1 May 2021]

*Press Releases*
Apr. 27, 2021
**Wistar Expands International Training of the Next Generation of Scientists With the University of Bologna**
Second international training program offers mentorship under top cancer research scientists.

**WFPHA: World Federation of Public Health Associations** [to 1 May 2021]
https://www wfpha.org/

*Latest News*
COVID-19 a Springboard for Immunization for All Ages

News  Apr 29, 2021

The WFPHA has used World Immunisation Week to call for greater coordination in the vaccination of people of all ages.

World Bank  [to 1 May 2021]

Selected News, Announcements

World Bank Expands Colombia Amazon Conservation Project with US$18.4 Million Grant

Washington, D.C., April 30, 2021 – The World Bank Board of Directors today approved an additional grant of US$18.4 million from the Global Environment Facility (GEF) for the Forest Conservation...

Date: April 30, 2021 Type: Press Release

Lebanon Financing Facility Approves $55 million Recovery Program Targeting Vulnerable Households and Small Businesses to Respond to the Port of Beirut Explosion

Beirut, April 30, 2021 – The World Bank convened yesterday the first meeting of the Partnership Council for the Lebanon Financing Facility (LFF) to discuss the priorities, proposed funding allocations...

Date: April 29, 2021 Type: Press Release

Lebanon Financing Facility for Reform, Recovery and Reconstruction (LFF)- Questions and Answers

Following the Port of Beirut explosion on August 4, 2020, the World Bank Group, the European Union and the United Nations developed the Reform, Recovery and Reconstruction Framework (3RF) in order to address...

Date: April 29, 2021 Type: Brief

Living with Debt: How Institutions Can Chart a Path to Recovery in the Middle East and North Africa

Authors: Gatti, Roberta; Lederman, Daniel; Nguyen, Ha M.; Alturki, Sultan Abdulaziz.; Fan, Rachel Yuting; Islam, Asif M.; Rojas, Claudio More than a year after the World Health Organization declared...

Date: April 28, 2021 Type: Brief

Supporting teachers using technology: 400 solutions from 80 countries

The World Bank Group and HundrED teamed up, supported with funding from the Global Partnership for Education (GPE), to launch the Teachers for a Changing World: Transforming Teacher Professional Development...

Date: April 28, 2021 Type: Feature Story

What is learning poverty?

All children should be able to read by age 10. Reading is a gateway for learning as the child progresses through school—and conversely, an inability to read slams that gate shut. Beyond this, when children...

Date: April 28, 2021 Type: Brief

Moldova’s Vaccination System to be Strengthened, with World Bank Support
WASHINGTON, April 27, 2021 – The World Bank has approved Additional Financing for the Moldova COVID-19 Emergency Response Project in the amount of EUR 24.8 million, which will support the Government of...

Date: April 27, 2021 Type: Press Release

**World Bank**

**World Bank Supports Fair and Effective Deployment of COVID-19 Vaccines in Sri Lanka**
WASHINGTON, April 27, 2021—The World Bank today approved $80.5 million additional financing to help Sri Lanka access and distribute COVID-19 vaccines and to strengthen the country’s vaccination system...

Date: April 27, 2021 Type: Press Release

---

**World Customs Organization – WCO** [to 1 May 2021]
http://www.wcoomd.org/
*Latest News – Selected Items*
*No new digest content identified.*

---

**World Organisation for Animal Health (OIE)** [to 1 May 2021]
*Press Releases*
*No new digest content identified.*

---

**WTO - World Trade Organisation** [to 1 May 2021]
http://www.wto.org/english/news_e/news_e.htm
*WTO News and Events*
*No new digest content identified.*

---

**ARM [Alliance for Regenerative Medicine]** [to 1 May 2021]
Press Releases - Alliance for Regenerative Medicine (alliancerm.org)
*Press Releases*
*No new digest content identified.*

---

**BIO** [to 1 May 2021]
*Press Releases*
*No new digest content identified.*

---

**DCVMN – Developing Country Vaccine Manufacturers Network** [to 1 May 2021]
http://www.dcvmn.org/
*News; Upcoming events*
*No new digest content identified.*
IFPMA statement at the close of the 3rd Fair Pricing Forum 13 to 22 April
Published on: 23 April 2021
We thank the organizers, World Health Organization and Ministry of Health of Argentina for convening this meeting and for inviting representatives from the innovative biopharmaceutical industry to share our experience and perspectives on how we can work collectively toward improved access to medicines worldwide.

It is with this mindset that we engaged in a constructive and open dialogue, aimed at co-creating solutions to our common objective of bringing innovative medicines to more patients around the world. We remain committed to maintaining the course in reaching the Sustainable Development Goals health targets, despite the coronavirus pandemic. The innovative biopharmaceutical industry is sensitive to the debate about affordability and access. We are making progress through new partnerships in reaching many more patients and supporting health systems for sustainable and longstanding improvements to patient health outcomes. There is still work to be done; and there is no room for complacency.

The coronavirus pandemic has shown how the innovative biopharmaceutical industry has risen to the occasion and to meet societal expectations in developing and scaling up manufacturing of tests, treatments, and vaccines, driven by a strong belief that in the end science will win and help us to overcome the pandemic. There are challenges to overcome in meeting the goal of “no one is safe until everyone is safe”, but we have also seen the power of public-private partnerships, such as Covax, and the critical role of vaccine manufacturers from industrialized as well as developing countries in scaling up production from zero to billions of doses in record time.

As discussed in prior editions of the Fair Pricing Forum, “fair pricing and fair access” should be achieved while ensuring continued support for an innovation ecosystem that allows future discoveries for today and tomorrow’s unmet medical needs. The COVID-19 innovations and roll out that have been achieved for the pandemic as a response to the biggest public health crisis of our age, cannot be assumed to be the norm. The unprecedented actions industry has taken for the coronavirus public health pandemic IS NOT BUSINESS AS USUAL. We have been able to respond in the manner that we have by leaning on the knowledge, know-how and pillars of a functioning innovation eco-system, built on decades of on-going investment.

We want to be better-prepared for future pandemics. To enable this, the fundamentals that have enabled our industry’s readiness to swiftly take on the COVID challenge should not be compromised.
New PhRMA report shows nearly 90 medicines in development to fight drug-resistant infections, but future pipeline remains challenging
April 29, 2021

New PhRMA report shows nearly 90 medicines in development to fight drug-resistant infections, but future pipeline remains challenging

Patient safety is at the heart of COVID-19 vaccine R&D
April 26, 2021

Patient safety is at the heart of COVID-19 vaccine R&D. Robust clinical research standards, safety monitoring, expert guidance, and genomic surveillance efforts all contribute to a robust safety practice surrounding our vaccine manufacturing and distribution ecosystem.

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 12, 2020 Issue 2
https://www.tandfonline.com/toc/uabr21/current
[Reviewed earlier]

AMA Journal of Ethics

Volume 23, Number 5: E371-433 May 2021
https://journalofethics.ama-assn.org/issue/ending-hiv-epidemic

Ending the HIV Epidemic

A human immunodeficiency virus (HIV) epidemic began in the United States in the 1970s. “Ending the HIV Epidemic: A Plan for America” was launched in October 2019 by the US Department of Health and Human Services, with the goal of stopping the spread of HIV by 2030. Accomplishing this goal demands not only expanding existing programs, but recognizing and responding to clinically, ethically, socially, and culturally relevant features of contemporary patients’ experiences of stigma, oppression,
and living with HIV. This issue considers ethical and clinical complexities patients and clinicians encounter in HIV care today.

**American Journal of Infection Control**
May 2021 Volume 49 Issue 5 p533-656
http://www.ajicjournal.org/current

*Major Articles*

**Trends in place of early-season influenza vaccination among adults, 2014-15 through 2018-19 influenza seasons—The importance of medical and nonmedical settings for vaccination**
Peng-jun Lu, Anup Srivastav, Tammy A. Santibanez,...Jessica Roycroft, Marshica Stanley Kurtz, Walter W. Williams
Published online: October 07, 2020
p555-562

*State of the Science Review*

**Paediatric nurses’, children’s and parents’ adherence to infection prevention and control and knowledge of antimicrobial stewardship: A systematic review**
Mataya Kilpatrick, Ana Hutchinson, Elizabeth Manias, Stéphane L. Bouchoucha
Published online: December 04, 2020
p622-639

*Open Access*

*Highlights*

:: This review provides compelling evidence that there is a lack of understanding of infection prevention and control precautions and appropriate antimicrobial use by parents, children, and nurses in paediatric settings.
:: Identified practice gaps highlight health care workers’, parents’ and children's vulnerability to pathogen exposure in the context of pandemic spread of highly contagious pathogens.
:: Parents and children had limited knowledge in relation to antimicrobials, and thus were making poor decisions on antibiotic use.
:: Nurses were unaware of their leadership role in antimicrobial stewardship but they nevertheless had a good understanding of antimicrobial stewardship principles and the barriers to good antimicrobial stewardship.

**American Journal of Preventive Medicine**
May 2021 Volume 60 Issue 5 p595-736
http://www.ajpmonline.org/current

*Research Articles*

**The Benefits of Vaccinating With the First Available COVID-19 Coronavirus Vaccine**
Sarah M. Bartsch, Kelly J. O'Shea, Patrick T. Wedlock, ...Sarah N. Cox, Peter J. Hotez, Bruce Y. Lee
Published online: January 18, 2021
p605-613

**Availability of Adult Vaccination Services by Provider Type and Setting**
Charleigh J. Granade,
Russell F. McCord,
American Journal of Public Health
May 2021  111(5)
http://ajph.aphapublications.org/toc/ajph/current

EDITORIALS
Partisan and Other Gaps in Support for COVID-19 Mitigation Strategies Require Substantial Attention
Immunization/Vaccines, Health Promotion, Media
Sarah E. Gollust
111(5), pp. 765–767

Essential Strategies to Curb COVID-19 Transmission in Prisons and Jails
Community Health, Health Policy, Epidemiology
Alexandria Macmadu and Lauren Brinkley-Rubinstein
111(5), pp. 776–777

American Journal of Tropical Medicine and Hygiene
https://www.ajtmh.org/view/journals/tpmd/104/4/tpmd.104.issue-4.xml
[Reviewed earlier]

Annals of Internal Medicine
April 2021  Volume 174, Issue 4
http://annals.org/aim/issue
[Reviewed earlier]

Artificial Intelligence – An International Journal
Volume 294  May 2021
[New issue; No digest content identified]

BMC Cost Effectiveness and Resource Allocation
http://resource-allocation.biomedcentral.com/
(Accessed 1 May 2021)
[No new digest content identified]

BMJ Global Health
April 2021 - Volume 6 - 4
BMC Health Services Research
http://www.biomedcentral.com/bmchealthservres/content
(Accessed 1 May 2021)
[No new digest content identified]

BMC Infectious Diseases
http://www.biomedcentral.com/bmcinfectdis/content
(Accessed 1 May 2021)
Correction to: Predictors of willingness to get a COVID-19 vaccine in the U.S
An amendment to this paper has been published and can be accessed via the original article.
Authors: Bridget J. Kelly, Brian G. Southwell, Lauren A. McCormack, Carla M. Bann, Pia D. M. MacDonald, Alicia M. Frasier, Christine A. Bevc, Noel T. Brewer and Linda B. Squiers
Citation: BMC Infectious Diseases 2021 21:383
Content type: Correction
Published on: 26 April 2021

BMC Medical Ethics
http://www.biomedcentral.com/bmcmedethics/content
(Accessed 1 May 2021)
Normative framework of informed consent in clinical research in Germany, Poland, and Russia
Biomedical research nowadays is increasingly carried out in multinational and multicenter settings. Due to disparate national regulations on various ethical aspects, such as informed consent, there is the risk...
Authors: Marcin Orzechowski, Katarzyna Woniak, Cristian Timmermann and Florian Steger
Citation: BMC Medical Ethics 2021 22:53
Content type: Research
Published on: 1 May 2021

Ethics review of big data research: What should stay and what should be reformed?
Ethics review is the process of assessing the ethics of research involving humans. The Ethics Review Committee (ERC) is the key oversight mechanism designated to ensure ethics review. Whether or not this gover...
Authors: Agata Ferretti, Marcello Ienca, Mark Sheehan, Alessandro Blasimme, Edward S. Dove, Bobbie Farsides, Phoebe Friesen, Jeff Kahn, Walter Karlen, Peter Kleist, S. Matthew Liao, Camille Nebeker, Gabrielle Samuel, Mahsa Shabani, Minerva Rivas Velarde and Effy Vayena
Citation: BMC Medical Ethics 2021 22:51
Content type: Debate
Published on: 30 April 2021

A scoping review of the literature featuring research ethics and research integrity cases
The areas of Research Ethics (RE) and Research Integrity (RI) are rapidly evolving. Cases of research misconduct, other transgressions related to RE and RI, and forms of ethically questionable behaviors have b...
Authors: Anna Catharina Vieira Armond, Bert Gordijn, Jonathan Lewis, Mohammad Hosseini, János Kristóf Bodnár, Soren Holm and Péter Kakuk
Citation: BMC Medical Ethics 2021 22:50
Content type: Research article
Published on: 30 April 2021

Recognising values and engaging communities across cultures: towards developing a cultural protocol for researchers
Efforts to build research capacity and capability in low and middle income countries (LMIC) has progressed over the last three decades, yet it confronts many challenges including issues with communicating or e...
Authors: Rakhshi Memon, Muqaddas Asif, Ameer B. Khoso, Sehrish Tofique, Tayyaba Kiran, Nasim Chaudhry, Nusrat Husain and Sarah J. L. Edwards
Citation: BMC Medical Ethics 2021 22:47
Content type: Debate
Published on: 26 April 2021

BMC Medicine
http://www.biomedcentral.com/bmcmed/content
(Accessed 1 May 2021)
[No new digest content identified]

BMC Pregnancy and Childbirth
http://www.biomedcentral.com/bmcpregnancychildbirth/content
(Accessed 1 May 2021)
[No new digest content identified]

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 1 May 2021)
Change in full immunization inequalities in Indian children 12–23 months: an analysis of household survey data
India has made substantial progress in improving child health in recent years. However, the country continues to account for a large number of vaccine preventable child deaths. We estimated wealth-related full...
Authors: Brian Wahl, Madhu Gupta, Daniel J. Erchick, Bryan N. Patenaude, Taylor A. Holroyd, Molly Sauer, Madeleine Blunt, Mathuram Santosham and Rupali Jayant Limaye
Citation: BMC Public Health 2021 21:841
Content type: Research article
Published on: 1 May 2021

Individual and social determinants of COVID-19 vaccine uptake
COVID-19 has had a devastating impact and efforts are being made to speed up vaccinations. The growing problem of vaccine hesitancy may affect the uptake of COVID-19 vaccine. We examined the individual, commun...
Authors: K. Viswanath, Mesfin Bekalu, Dhriti Dhawan, Ramya Pinnamaneni, Jenna Lang and Rachel McLoud
Citation: BMC Public Health 2021 21:818
Content type: Research article
Published on: 28 April 2021

Predicting intention to receive COVID-19 vaccine among the general population using the health belief model and the theory of planned behavior model
This study aim to explore the intentions, motivators and barriers of the general public to vaccinate against COVID-19, using both the Health Belief Model (HBM) and the Theory of Planned Behavior (TPB) model.
Authors: Liora Shmueli
Citation: BMC Public Health 2021 21:804
Content type: Research
Published on: 26 April 2021

BMC Research Notes
http://www.biomedcentral.com/bmcresnotes/content
(Accessed 1 May 2021)
[No new digest content identified]

BMJ Evidence-Based Medicine
April 2021 - Volume 26 - 2
https://ebm.bmj.com/content/26/2
[Reviewed earlier]

BMJ Open
March 2021 - Volume 11 - 4
https://bmjopen.bmj.com/content/11/4
[Reviewed earlier]

Bulletin of the World Health Organization
Volume 99, Number 4, April 2021, 241-320
[Reviewed earlier]

Cell
Apr 29, 2021 Volume 184 Issue 9p2259-2524
https://www.cell.com/cell/current
Commentary
Creating collaboration by breaking down scientific barriers
Jacqueline M. Fabius, Nevan J. Krogan

The scientific world rewards the individual while often discouraging collaboration. However, times of crisis show us how much more we can accomplish when we work together. Here, we describe our approach to breaking down silos and fostering global collaborations and share the lessons we have learned, especially pertaining to research on SARS-CoV-2.

Child Care, Health and Development
Volume 47, Issue 3 Pages: 297-410 May 2021
https://onlinelibrary.wiley.com/toc/13652214/current
[Reviewed earlier]

Clinical Pharmacology & Therapeutics
Volume 109, Issue 5 Pages: 1159-1362 May 2021
https://ascpt.onlinelibrary.wiley.com/toc/15326535/current
Perspective
Balancing Safety and Efficacy With Early Availability in the Regulation of Regenerative Medicine Product
Yasuhiro Fujiwara, Yoshiaki Maruyama, Futaba Honda
First published: 26 September 2020
https://doi.org/10.1002/cpt.2034

Reviews - White Paper
The Certainty Framework for Assessing Real-World Data in Studies of Medical Product Safety and Effectiveness
Noelle M. Cocoros, Peter Arlett, Nancy A. Dreyer, Chieko Ishiguro, Solomon Iyasu, Miriam Sturkenboom, Wei Zhou, Sengwee Toh
Pages: 1189-1196
First Published: 10 September 2020
Abstract
A fundamental question in using real-world data for clinical and regulatory decision making is: How certain must we be that the algorithm used to capture an exposure, outcome, cohort-defining characteristic, or confounder is what we intend it to be? We provide a practical framework to help researchers and regulators assess and classify the fit-for-purposefulness of real-world data by study variable for a range of data sources. The three levels of certainty (optimal, sufficient, and probable) must be considered in the context of each study variable, the specific question being studied, the study design, and the decision at hand.

Review - Open Access
Randomized Controlled Trials Versus Real World Evidence: Neither Magic Nor Myth
Hans-Georg Eichler, Francesco Pignatti, Brigitte Schwarzer-Daum, Ana Hidalgo-Simon, Irmgard Eichler Peter Arlett, Anthony Humphreys, Spiros Vamvakas, Nikolai Brun, Guido Rasi
Pages: 1212-1218
First Published: 16 October 2020
Abstract
Compared with drugs from the blockbuster era, recently authorized drugs and those expected in the future present a heterogenous mix of chemicals, biologicals, and cell and gene therapies, a sizable fraction being for rare diseases, and even individualized treatments or individualized combinations. The shift in the nature of products entails secular trends for the definitions of “drugs” and “target population” and for clinical use and evidence generation. We discuss that the lessons learned from evidence generation for 20th century medicines may have limited relevance for 21st century medicines. We explain why the future is not about randomized controlled trials (RCTs) vs. real-world evidence (RWE) but RCTs and RWE—not just for the assessment of safety but also of effectiveness. Finally, we highlight that, in the era of precision medicine, we may not be able to reliably describe some small treatment effects—either by way of RCTs or RWE.

Clinical Therapeutics
Volume 43  Issue 3  p431-650, e57-e96
http://www.clinicaltherapeutics.com/current
[Reviewed earlier]

Clinical Trials
Volume 18  Issue 2, April 2021
https://journals.sagepub.com/toc/ctja/18/2
[Reviewed earlier]

Conflict and Health
http://www.conflictandhealth.com/
[Accessed 1 May 2021]
[No new digest content identified]

Contemporary Clinical Trials
Volume 103  April 2021
https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/103/suppl/C
[New issue; No digest content identified]

The CRISPR Journal
Volume 4, Issue 2 / April 2021
https://www.liebertpub.com/toc/crispr/4/2
[Reviewed earlier]

Current Genetic Medicine Reports
Volume 9, issue 2, June 2021
[New issue; No digest content identified]
Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar [PDF - 1.44 MB - 10 pages]
A. Jeremijenko et al.

Epidemics
Volume 34  March 2021
https://www.sciencedirect.com/journal/epidemics/vol/34/suppl/C
[Reviewed earlier]

Epidemiology and Infection
Volume 149 - 2021
https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue
[Reviewed earlier]

Ethics & Human Research
Volume 43, Issue 2  Pages: 1-48  March–April 2021
https://onlinelibrary.wiley.com/toc/25782363/current

Research ethics and pandemics • IRBs and AI research
[Reviewed earlier]

The European Journal of Public Health
Volume 31, Issue 2, April 2021
https://academic.oup.com/eurpub/issue/31/2

Health services research
Public support for European cooperation in the procurement, stockpiling and distribution of medicines
Roel Beetsma, Brian Burgoon, Francesco Nicoli, Anniek de Ruijter, Frank Vandenbroucke
European Journal of Public Health, Volume 31, Issue 2, April 2021, Pages 253–258,
https://doi.org/10.1093/eurpub/ckaa201

Conclusion
Joint procurement raises delicate questions with regard to its scope, the inclusion of cross-border solidarity and the delegation of decision-making, that explain reluctance toward joint procurement among political decision-makers. This research shows that there is considerable public support across different countries in favor of centralization, i.e. a large scope and solidarity in the allocation and delegation of decision-making.

Infectious disease
Coverage rates against vaccine-preventable diseases among healthcare workers in Sicily (Italy)
Caterina Ledda, Venerando Rapisarda, Helena C Maltezou, Eleonora Contrino, Arianna Conforto ...
European Journal of Public Health, Volume 31, Issue 1, February 2021, Page 56,
https://doi.org/10.1093/eurpub/ckaa179
Expert Review of Vaccines
Vol 20 (2) 2021
https://www.tandfonline.com/toc/ierv20/current
Reviewed earlier

Gates Open Research
https://gatesopenresearch.org/browse/articles
Accessed 1 May 2021
No new digest content identified

Genome Medicine
https://genomemedicine.biomedcentral.com/articles
Accessed 1 May 2021
Reviewed earlier

Global Health Action
Volume 14, Issue 1 (2021)
https://www.tandfonline.com/toc/zgha20/current?nav=tocList
Reviewed earlier

Global Health: Science and Practice (GHSP)
Vol. 9, No. 1 April 01, 2021
http://www.ghspjournal.org/content/current
Reviewed earlier

Global Public Health
Volume 16, Issue 5 (2021)
http://www.tandfonline.com/toc/rgph20/current
Special Issue: The Contested Global Politics of Pleasure and Danger: Sexuality, Gender, Health and Human Rights; Guest Editors: Carmen H. Logie, Amaya Perez-Brumer and Richard Parker
Article
Intersex care in the United States and international standards of human rights
Juan Carlos Jorge, Leidy Valerio-Pérez, Caleb Esteban & Ana Irma Rivera-Lassen
Pages: 679-691
Published online: 24 Dec 2019
Article
Intersex care in the United States and international standards of human rights
Juan Carlos Jorge, Leidy Valerio-Pérez, Caleb Esteban & Ana Irma Rivera-Lassen
Pages: 679-691
Published online: 24 Dec 2019
Globalization and Health
http://www.globalizationandhealth.com/
[Accessed 1 May 2021]
[No new digest content identified]

Health Affairs
Vol. 40, No. 3 March 2021
https://www.healthaffairs.org/toc/hlthaff/current
March 2021 / Nursing Homes, COVID-19 & More
[Reviewed earlier]

Health and Human Rights
Volume 22, Issue 1, June 2020
Special Section: Mental Health and Human Rights
[New issue; No digest content identified]

Health Economics, Policy and Law
Volume 16 - Issue 2 - April 2021
https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue
[Reviewed earlier]

Health Policy and Planning
Volume 36, Issue 3, April 2021
https://academic.oup.com/heapol/issue/36/3
ORIGINAL ARTICLES
The role of government agencies and other actors in influencing access to medicines in three East African countries
Walter Denis Odoch, Yoswa Dambisya, Elizabeth Peacocke, Kristin Ingstad Sandberg, Berit Sofie Hustad Hembre
Health Policy and Planning, Volume 36, Issue 3, April 2021, Pages 312–321,
https://doi.org/10.1093/heapol/czaa189

COMMENTARIES
Remote data collection for public health research in a COVID-19 era: ethical implications, challenges and opportunities
B Hensen, C R S Mackworth-Young, M Simwinga, N Abdelmagid, J Banda ...
Health Policy and Planning, Volume 36, Issue 3, April 2021, Pages 360–368,
https://doi.org/10.1093/heapol/czaa158

Health Research Policy and Systems
http://www.health-policy-systems.com/content
[Accessed 1 May 2021]
Humanitarian Exchange Magazine  
Number 78, October 2020

Disability inclusion in humanitarian action  
by HPN October 2020

The theme of this edition of Humanitarian Exchange, co-edited with Sherin Alsheikh Ahmed from Islamic Relief Worldwide, is disability inclusion in humanitarian action. Persons with disabilities are not only disproportionately impacted by conflicts, disasters and other emergencies, but also face barriers to accessing humanitarian assistance. At the same time, global commitments and standards and the IASC Guidelines on the inclusion of persons with disabilities in humanitarian action all emphasise how persons with disabilities are also active agents of change. Disability and age-focused organisations have led on testing and demonstrating how inclusion can be done better. Yet despite this progress, challenges to effective inclusion remain.

As Kirstin Lange notes in the lead article, chief among these challenges is humanitarian agencies’ lack of engagement with organisations of persons with disabilities. Simione Bula, Elizabeth Morgan and Teresa Thomson look at disability inclusion in humanitarian response in the Pacific, and Kathy Al Jubeh and Alradi Abdalla argue for a ‘participation revolution’, building on learning from the gender movement. Tchaurea Fleury and Sulayman AbdulMumuni Ujah outline how the Bridge Article 11 training initiative is encouraging constructive exchange between humanitarian and disability actors. The lack of good, disaggregated data is highlighted by Sarah Collinson; Frances Hill, Jim Cranshaw and Carys Hughes emphasise the need for training resources in local languages and accessible formats; and Sophie Van Eetvelt and colleagues report on a review of the evidence on inclusion of people with disabilities and older people.

Rebecca Molyneux and co-authors analyse the findings of a review of a DFID programme in north-east Nigeria, while Carolin Funke highlights the importance of strategic partnerships between disability-focused organisations, drawing on her research in Cox’s Bazar. Sherin Alsheikh Ahmed describes Islamic Relief Worldwide’s approach to mainstreaming protection and inclusion, while Pauline Thivillier and Valentina Shafina outline IRC’s Client Responsive Programming. The edition ends with reflections by Mirela Turcanu and Yves Ngunzi Kahashi on CAFOD’s SADI approach.
Infectious Agents and Cancer
http://www.infectagentscancer.com/content
[Accessed 1 May 2021]
[No new digest content identified]

Infectious Diseases of Poverty
http://www.idpjournal.com/content
[Accessed 1 May 2021]
**Demand for longer quarantine period among common and uncommon COVID-19 infections: a scoping review**
Authors: Zhi-Yao Li, Yu Zhang, Liu-Qing Peng, Rong-Rong Gao, Jia-Rui Jing, Jia-Le Wang, Bin-Zhi Ren, Jian-Guo Xu and Tong Wang
Content type: Scoping Review
26 April 2021

International Health
Volume 13, Issue 3, May 2021
https://academic.oup.com/inthealth/issue/13/3
*EDITORIAL*
**Disrupting vaccine logistics**
Eric R James
International Health, Volume 13, Issue 3, May 2021, Pages 211–214,
https://doi.org/10.1093/inthealth/ihab010

*REVIEW ARTICLES*
**Rethinking disease eradication: putting countries first**
Teshome Gebre
International Health, Volume 13, Issue 3, May 2021, Pages 215–221,
https://doi.org/10.1093/inthealth/ihab011

International Journal of Community Medicine and Public Health
Vol 8, No 5 (2021) May 2021
https://www.ijcmph.com/index.php/ijcmph/issue/view/76
*Original Research Articles*
**Predictors of acceptance of COVID-19 vaccine among patients at a tertiary hospital in South-South Nigeria**
Dennis O. Allagoa, Peter Chibuzor Oriji, Ebiye S. Tekenah, Lukman Obagah, Chidiebere Njoku, Adeniyi Stephen Afolabi, Gordon Atemie
DOI: 10.18203/2394-6040.ijcmph20211733

*Editorial*
**Continuing COVID vaccination will break the chain of virus transmission: myth or reality**
Achhelal R. Pasi
International Journal of Epidemiology  
Volume 50, Issue 1, February 2021  
https://academic.oup.com/ije/issue  
[Reviewed earlier]  

International Journal of Human Rights in Healthcare  
Volume 14 Issue 1 2021  
https://www.emerald.com/insight/publication/issn/2056-4902/vol/14/iss/1  
Table of Contents  
[Reviewed earlier]  

International Journal of Infectious Diseases  
Volume 105 p1-784  
https://www.ijidonline.com/current  
Coronavirus (COVID-19) Collection  
Prioritizing second-generation SARS-CoV-2 vaccines through low-dosage challenge studies  
Bastian Steuwer, Euzebiusz Jamrozik, Nir Eyal  
Published online: February 12, 2021  
p307-311  

COVID-19 vaccines: Global challenges and prospects forum recommendations  
Mohamed Boudjelal, Faisal Almajed, Ahmed M. Salman,...Mariwan Baker, Adrian V.S. Hill, Ahmed Alaskar  
Published online: February 26, 2021  
p448-451  

Original Reports  
Increasing vaccine acceptance using evidence-based approaches and policies: Insights from research on behavioural and social determinants presented at the 7th Annual Vaccine Acceptance Meeting  
Katie Attwell, Cornelia Betsch, Eve Dubé, ...L. Suzanne Suggs, Valentina Picot, Angus Thomson  
Published online: February 09, 2021  
p188-193  

Rotavirus genotype trends from 2013 to 2018 and vaccine effectiveness in southern Vietnam  
Dung Thi Thuy Truong, Ji-Man Kang, Ngoc Thi Hong Tran,...Sangchul Yoon, Thuong Vu Nguyen, Joon-Sup Yeom  
Published online: February 14, 2021  
p277-285  

JAMA  
April 27, 2021, Vol 325, No. 16, Pages 1593-1688  
https://jamanetwork.com/journals/jama/currentissue  
Research Letter
HPV Vaccination Among Young Adults in the US
Michelle M. Chen, MD, MHS; Nicole Mott, BS; Sarah J. Clark, MPH; et al.

This study uses data from the 2010-2018 National Health Interview Survey to characterize trends in human papillomavirus (HPV) vaccination rates, ages at vaccination, and numbers of doses received among young adults in the US between 2010 and 2018.

JAMA Insights
First-Dose COVID-19 Vaccination Coverage Among Skilled Nursing Facility Residents and Staff
Radhika Gharpure, DVM, MPH; Anita Patel, PharmD, MS; Ruth Link-Gelles, PhD, MPH
has active quiz has audio

This JAMA Insights review from CDC COVID-19 Response team members presents data on the number of long-term care facilities and the numbers of residents and staff of those facilities who received first-dose vaccination through mid-January 2021 under the agency’s public-private partnership with CVS, Walgreens, and Managed Health Care Associates.

JAMA Network
COVID-19 Update May 1, 2021
These articles on COVID-19 were published across the JAMA Network in the last week.

JAMA Pediatrics
April 2021, Vol 175, No. 4, Pages 339-440
https://jamanetwork.com/journals/jamapediatrics/currentissue
[Reviewed earlier]

JBI Evidence Synthesis
April 2021 - Volume 19 - Issue 4
https://journals.lww.com/jbisrir/Pages/currenttoc.aspx
[Reviewed earlier]

Journal of Adolescent Health
Volume 68 Issue 5 p833-1024
https://www.jahonline.org/current
[Reviewed earlier]

Journal of Artificial Intelligence Research
Vol. 70 (2021)
https://www.jair.org/index.php/jair
[Reviewed earlier]
Journal of Community Health
Volume 46, issue 2, April 2021
[Reviewed earlier]

Journal of Development Economics
Volume 150 May 2021
[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics
Volume 16 Issue 1-2, February-April 2021
http://journals.sagepub.com/toc/jre/current
[Reviewed earlier]

Journal of Epidemiology & Community Health
May 2021 - Volume 75 - 5
https://jech.bmj.com/content/75/5
[New issue; No digest content identified]

Journal of Evidence-Based Medicine
Volume 14, Issue 1 Pages: 1-81 February 2021
https://onlinelibrary.wiley.com/toc/17565391/current
[Reviewed earlier]

Journal of Global Ethics
Volume 16, Issue 2, 2020
http://www.tandfonline.com/toc/rjge20/current
[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)
Volume 32, Number 1, February 2021
https://muse.jhu.edu/issue/43951
Table of Contents
[Reviewed earlier]

Journal of Immigrant and Minority Health
Volume 23, issue 3, June 2021
[New issue; No digest content identified]
Journal of Immigrant & Refugee Studies
Volume 19, 2021, Issue 2
https://www.tandfonline.com/toc/wimm20/current
[Reviewed earlier]

Journal of Infectious Diseases
Volume 223, Issue 6, 15 March 2021
https://academic.oup.com/jid/issue/223/6
[New issue; No digest content identified]

Journal of Medical Ethics
May 2021 - Volume 47 - 5
http://jme.bmj.com/content/current
COVID-19 current controversies
Nancy S Jecker, Aaron G Wightman, Douglas S Diekema

Original research
Process of risk assessment by research ethics committees: foundations, shortcomings and open questions (10 January, 2020)
Pranab Rudra, Christian Lenk

Journal of Patient-Centered Research and Reviews
Volume 8, Issue 2 (2021)
https://digitalrepository.aurorahealthcare.org/jpcrr/
[Reviewed earlier]

Journal of Pediatrics
Volume 232, pp 1-316
http://www.jpeds.com/current
[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice
https://joppp.biomedcentral.com/
[Accessed 1 May 2021]
Online medication purchasing during the Covid-19 pandemic: potential risks to patient safety and the urgent need to develop more rigorous controls for purchasing online medications, a pilot study from the United Arab Emirates
Since the WHO announced that Covid-19 had become a global pandemic, online pharmacies have emerged as an extremely popular way to purchase medication due to the quarantine measures introduced by numerous count...
Journal of Public Health Management & Practice

May/June 2021 - Volume 27 - Issue 3
https://journals.lww.com/jphmp/pages/currenttoc.aspx

Editorials

An Ace Up Our Sleeves: The COVID-19 Vaccine Rollout Revealed Our Strengths and Our Neglected Public Health Infrastructure
Pierce, Heather H.

Commentary

Maintaining a Focus on Health Equity During the COVID-19 Vaccine Rollout
Martin, Erika G.; Birkhead, Guthrie S.; Holtgrave, David R.

Journal of Public Health Policy

Volume 42, issue 1, March 2021
https://link.springer.com/journal/41271/volumes-and-issues/42-1
[Reviewed earlier]

Journal of Refugee & Global Health

Volume 4, Issue 1 (2021)
https://ir.library.louisville.edu/rgh/
[Reviewed earlier]

Journal of the Royal Society – Interface

April 2021  Volume 18  Issue 177
https://royalsocietypublishing.org/toc/rsif/current
[Reviewed earlier]

Journal of Travel Medicine

Volume 28, Issue 3, April 2021
https://academic.oup.com/jtm/issue
[Reviewed earlier]

Journal of Virology

May 2021; Volume 95, Issue 10
**Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study**
Eleftheria Vasileiou, et al
Open Access

**Summary**

**Background**
The BNT162b2 mRNA (Pfizer–BioNTech) and ChAdOx1 nCoV-19 (Oxford–AstraZeneca) COVID-19 vaccines have shown high efficacy against disease in phase 3 clinical trials and are now being used in national vaccination programmes in the UK and several other countries. Studying the real-world effects of these vaccines is an urgent requirement. The aim of our study was to investigate the association between the mass roll-out of the first doses of these COVID-19 vaccines and hospital admissions for COVID-19.

**Findings**
Between Dec 8, 2020, and Feb 22, 2021, a total of 1 331 993 people were vaccinated over the study period. The mean age of those vaccinated was 65·0 years (SD 16·2). The first dose of the BNT162b2 mRNA vaccine was associated with a vaccine effect of 91% (95% CI 85–94) for reduced COVID-19 hospital admission at 28–34 days post-vaccination. Vaccine effect at the same time interval for the ChAdOx1 vaccine was 88% (95% CI 75–94). Results of combined vaccine effects against hospital admission due to COVID-19 were similar when restricting the analysis to those aged 80 years and older (83%, 95% CI 72–89 at 28–34 days post-vaccination).

**Interpretation**
Mass roll-out of the first doses of the BNT162b2 mRNA and ChAdOx1 vaccines was associated with substantial reductions in the risk of hospital admission due to COVID-19 in Scotland. There remains the possibility that some of the observed effects might have been due to residual confounding.

**Funding**
UK Research and Innovation (Medical Research Council), Research and Innovation Industrial Strategy Challenge Fund, Health Data Research UK.

**Clinical Picture**

**Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination**
Antonios Bayas, Martina Menache, Monika Christ, Lars Behrens, Andreas Rank, Markus Naumann
Can technology increase COVID-19 vaccination rates?

The Lancet Digital Health

... To manage the wealth of data from adverse events tracking, the MHRA have awarded £1.5 million to develop AI that can identify genuine COVID-19 vaccine adverse effects. While experts have applauded the MHRA's forward thinking approach, development of AI based on limited self-reported public data and electronic health records that are subject to historic and systemic bias must be validated on data from minority and other at-risk populations to maintain trust within these communities.

To combat bias in datasets and algorithms, transparent auditing of clinical AI tools is essential to accurately communicate results to the public for greater vaccine uptake. As the UK and the USA pass the milestones of 20 million and 100 million people (respectively) vaccinated against COVID-19, associated data must be made transparent and accessible. Datasets such as the England and Wales COVID-19 vaccination datasets, which are available upon request to researchers, are critical to communicate real-world effectiveness of the vaccine to the public.

President Biden has recently pledged over $500 million in additional funds to address vaccine uptake in the USA. This funding must be spent on establishing transparent COVID-19 vaccine data to aid informed public decisions. Technology can help monitor progress of vaccine programmes, but it will not be enough to establish trust among the public, especially among those most at risk.
**Lancet Infectious Diseases**
May 2021  Volume 21  Number 5  p579-742, e110-e140
https://www.thelancet.com/journals/laninf/issue/current

*Editorial*

“In an ocean of ashes, islands of order”: WHO’s SARS-CoV-2 origin report
The Lancet Infectious Diseases

*Comment*

First immunogenicity data for the UK serogroup B meningococcal vaccination schedule in infants
Lucy A McNamara, Sarah Mbaeyi

Effectiveness of rotavirus vaccine in preventing transmission of rotavirus from children to household contacts in Malawi
Tisungane Edward Mwenyenkulu, Peter Austin Morton Ntenda

*Articles*

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial
Raches Ella, et al

Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trial
Kimberly Davis, et al

Community transmission of rotavirus infection in a vaccinated population in Blantyre, Malawi: a prospective household cohort study
Aisleen Bennett, et al

Open Access

**Lancet Public Health**
May 2021  Volume 6  Number 5  e260-e345
https://www.thelancet.com/journals/lanpub/issue/current

*Editorial*

Renewing the fight to end tuberculosis
The Lancet Public Health

*Articles*

Community-based active case-finding interventions for tuberculosis: a systematic review
Rachael M Burke, et al

Incidence and prevalence of tuberculosis in incarcerated populations: a systematic review and meta-analysis
Olivia Cords, et al
**Lancet Respiratory Medicine**  
May 2021 Volume 9 Number 5 p435-544, e47-e50  
https://www.thelancet.com/journals/lanres/issue/current  
[New issue: No digest content identified]

**Maternal and Child Health Journal**  
Volume 25, issue 5, May 2021  
[New issue; No digest content identified]

**Medical Decision Making (MDM)**  
Volume 41 Issue 4, May 2021  
http://mdm.sagepub.com/content/current  
Review  
The Use and Misuse of Mathematical Modeling for Infectious Disease Policymaking: Lessons for the COVID-19 Pandemic  
Lyndon P. James, Joshua A. Salomon, Caroline O. Buckee, Nicolas A. Menzies  
First Published February 3, 2021; pp. 379–385

**The Milbank Quarterly**  
A Multidisciplinary Journal of Population Health and Health Policy  
Volume 99, Issue 1 Pages: 1-327 March 2021  
https://onlinelibrary.wiley.com/toc/14680009/current  
[Reviewed earlier]

**Nature**  
Volume 592 Issue 7856, 29 April 2021  
https://www.nature.com/nature/volumes/592/issues/7856  
Editorial | 28 April 2021  
**It’s time to invite more people to join clinical trials**  
Drug trials need more participants. Research shows the potential benefits of changing the criteria used to determine who can enroll.

**Editorial | 28 April 2021**  
**To remedy health disparities, more scientists must ‘get political’**  
The pandemic has given scientists a more prominent voice in society. They need to use it to push for better health through equality.

**World View | 27 April 2021**  
**COVID vaccines: time to confront anti-vax aggression**  
Halting the spread of the coronavirus will require a high-level counteroffensive against new destructive forces.
Nearly one billion COVID-19 vaccine doses have been delivered in less than six months, but anti-vaccine disinformation and targeted attacks on scientists are undermining progress. These threats must be confronted directly, and the authority and expertise of the health community alone aren't enough to do this.

Even before the pandemic, I had a front-row seat to all of this. I have co-led efforts to develop vaccines in programmes, including a COVID-19 vaccine currently being tested in India. I also have an adult daughter with autism; my 2018 book, Vaccines Did Not Cause Rachel's Autism, became a dog whistle for anti-vaccine activists.

The World Health Organization recognized vaccine hesitancy as a top threat to global health before the pandemic. As COVID-19 vaccines moved through development, the public-health communities anticipated considerable vaccine hesitancy. Teams of experts, including me, began meeting regularly online to discuss how best to amplify evidence-based messages, deliver public-service announcements and address concerns around COVID-19 immunization.

I experienced sinking feelings during our Zoom calls. Although certainly worthwhile, I knew that messaging alone would be inadequate. We’d already seen this inadequacy in our efforts to prevent measles from returning to the United States and Europe in 2019, and to bolster vaccination rates for human papillomavirus to prevent cervical and other cancers. With COVID-19, our pro-vaccine messages would be drops in a vast sea of misinformation, much of it poured in deliberately by anti-vaccine forces.

I have a long-standing disagreement with many of my US public-health colleagues. I admire their commitment to disease prevention, but when I ask for a more direct way to counter anti-vaccine aggression, I’m told, “that’s not our approach; confrontation gives them a platform and oxygen.” In my opinion, this attitude reflects a time when we had dial-up modems. Today, the anti-vaccine empire has hundreds of websites and perhaps 58 million followers on social media. The bad guys are winning, in part because health agencies either underestimate or deny the reach of anti-science forces, and are ill-equipped to counter it.

Investigations by the US State Department and the UK Foreign Office have described how Russian intelligence organizations seek to discredit Western COVID-19 vaccines. One campaign implies that it could turn people into monkeys. This builds on a longer, well-documented history of Russia-sponsored disinformation, presumably to destabilize the United States and other democratic countries. The administration of US President Joe Biden has warned Russian media groups to halt their anti-vaccine aggression, and announced sanctions tied to disinformation and other behaviour, but we need much more.

The United States hosts the world’s largest and best-organized anti-vaccine groups. According to the London-based Center for Countering Digital Hate, these are influential groups, not a spontaneous grass-roots movement. Many far-right extremist groups that spread false information about last year's US presidential election are doing the same about vaccines. Anti-vaccine groups also target Black communities; an anti-vaccine documentary released in March vilifies COVID-19 vaccine testing among African Americans, calling it "medical racism".
Global anti-vaccine messaging around the adenovirus vaccines means that more people will die and the pandemic will be prolonged. Extremely rare but life-threatening blood clots caused the United States to pause roll-out of the Johnson & Johnson vaccine, and many European nations have stopped or restricted use of the Oxford–AstraZeneca vaccine for similar reasons. However, those regions have other vaccine options, which is not the case for many countries. In March, Cameroon and the Democratic Republic of the Congo halted use of the Oxford–AstraZeneca vaccine, and the African Union has stopped procurement.

Many people in Africa are tapping into anti-vaccine messaging. A rumour-tracking program from the analytics company Novetta in McLean, Virginia, finds that Russia specifically targets African countries to discredit Western vaccines in favour of its own Sputnik V. US-based anti-vaccine groups invoke colonialism and eugenics. Now, tens of thousands of vaccine doses are going unused. Anti-vaccine disinformation has turned reasonable questions and concerns over rare side effects into conspiracy worries, exaggerated fears, and outrage at being treated like ‘guinea pigs’.

Accurate, targeted counter-messaging from the global health community is important but insufficient, as is public pressure on social-media companies. The United Nations and the highest levels of governments must take direct, even confrontational, approaches with Russia, and move to dismantle anti-vaccine groups in the United States.

Efforts must expand into the realm of cyber security, law enforcement, public education and international relations. A high-level inter-agency task force reporting to the UN secretary-general could assess the full impact of anti-vaccine aggression, and propose tough, balanced measures. The task force should include experts who have tackled complex global threats such as terrorism, cyber attacks and nuclear armament, because anti-science is now approaching similar levels of peril. It is becoming increasingly clear that advancing immunization requires a counteroffensive.

**Nature Biotechnology**  
Volume 39 Issue 4, April 2021  
https://www.nature.com/nbt/volumes/39/issues/4  
[Reviewed earlier]

**Nature Communications**  
https://www.nature.com/subjects/health-sciences/ncomms  
(Accessed 1 May 2021)  
[No new digest content identified]

**Nature Genetics**  
Volume 53 Issue 4, April 2021  
https://www.nature.com/ng/volumes/53/issues/4  
[Reviewed earlier]

**Nature Human Behaviour**  
Volume 5 Issue 4, April 2021
The influence of evolutionary history on human health and disease

Our evolutionary history has resulted in highly complex and sophisticated human physiology. Yet evolutionary footprints have also left us prone to diseases. In this Review, the authors discuss how events from the earliest history of life on Earth through to modern human evolution influence many disease traits and outcomes. They describe how an understanding and application of evolutionary frameworks can inform precision medicine initiatives.

Mary Lauren Benton, Abin Abraham, John A. Capra

African genetic diversity and adaptation inform a precision medicine agenda

Africa is a continent with deep evolutionary history, which has implications for the genetic underpinnings of disease. In this Review, the authors discuss how genetic features of African populations provide both challenges and opportunities for understanding disease genetics in Africa. They describe how this genetic knowledge — combined with initiatives including capacity-building, data sharing and increased representation of African genomes in genetic variation databases — can be leveraged towards achieving precision medicine approaches in African healthcare.

Luisa Pereira, Leon Mutesa, Michèle Ramsay

Nature Reviews Immunology

Nature Reviews Drug Discovery

New England Journal of Medicine
Perspective

Vaccination plus Decarceration — Stopping Covid-19 in Jails and Prisons
Benjamin A. Barsky, J.D., M.B.E., Eric Reinhart, B.A., Paul Farmer, M.D., Ph.D., and Salmaan Keshavjee, M.D., Ph.D.

... Stopping the epidemic in jails and prisons is vital for protecting staff and incarcerated people; it is also critical for curbing the spread of Covid-19 into surrounding communities, especially Black and Latinx communities that are disproportionately affected by jail- and prison-linked coronavirus spread. Furthermore, as we become aware of an increasing range of SARS-CoV-2 variants, we face greater urgency to disrupt the ideal environment that current carceral conditions provide for viral mutations that could undermine the efficacy of available vaccines and threaten health far beyond American borders.

Vaccination of incarcerated people is important for changing this dynamic, but it is not enough. We believe that it must be coupled with large-scale decarceration to increase the real-world effectiveness of vaccination, disrupt wide-ranging viral transmission chains, and turn off the epidemiologic pump that puts the health of all at risk from mass incarceration.

Decarceration strategies can guide decisions made by a range of actors who wield power to change current conditions, including federal and state legislators, state and local law enforcement, prosecutors, judges, mayors, governors, the U.S. attorney general, and the president of the United States. We believe the medical community has a parallel responsibility to ensure that science is heard and applied. On the grounds of scientific evidence and our ethical responsibility to protect the vulnerable and the public at large, we can use our influence to demand that policymakers implement decarceration alongside priority vaccination in jails and prisons.

Leveraging Open Science to Accelerate Research
Kushal T. Kadakia, M.Sc., Adam L. Beckman, B.S., Joseph S. Ross, M.D., M.H.S., and Harlan M. Krumholz, M.D.

... The idea of embracing open science represents a vision for research conduct that promotes standard processes for sharing protocols and registering studies, reporting and disseminating results, and sharing data, biospecimens, and code. The advancement of science — an intrinsically iterative process — is contingent on reporting practices that enable data to be findable, accessible, interoperable, and reusable to permit independent scrutiny, replication, and follow-on investigations. Realizing the value of research and fostering trust in science requires study information to be readily available to the public and the scientific community, including in open-access journals and on preprint platforms. Over the past 20 years, policymakers and investigators have promoted open science to counteract clinical researchers’ tendency to sequester data. Such efforts have included the recent release of NIH data-sharing guidelines and public–private partnerships for data sharing, such as the Yale University Open Data Access Project (which two of us help to lead). The urgency associated with the pandemic has created an imperative to accelerate the adoption of open science...

Choices in a Crisis — Individual Preferences among SARS-CoV-2 Vaccines
Daniel B. Kramer, M.D., M.P.H., Douglas J. Opel, M.D., M.P.H., Efthimios Parasidis, J.D., M.B.E., and Michelle M. Mello, J.D., Ph.D.

... We believe that public health officials should anticipate these good-faith concerns and provide clear recommendations regarding accommodation of individual preferences. Nevertheless, at this point in the pandemic, we find countervailing considerations more compelling, and we recommend restricting patient choice. The key guideposts for this position are expediency, equity, and equanimity...
Health Outcomes in Young Children Following Pertussis Vaccination During Pregnancy
Meghan Laverty, Natasha Crowcroft, Shelly Bolotin, Steven Hawken, Kumanan Wilson, Gayatri Amirthalingam, Anne Biringer, Jocelynn Cook, Vinita Dubey, Romina Fakhraei, Scott A. Halperin, Frances Jamieson, Jeffrey C. Kwong, Manish Sadarangani, Ewa Sucha, Mark C. Walker, Deshayne B. Fell
Pediatrics, May 2021, 147 (5) e2020042507

Family Partnerships
Supporting Families Considering Participation in a Clinical Trial: Parent-Provider Perspectives
Terence R. Flotte, Blyth Taylor Lord, Jennifer Siedman
Pediatrics, May 2021, 147 (5) e2020042044

Promoting COVID-19 Vaccination on Social Media
Fajar Raza, John D. Lantos
Pediatrics, May 2021, 147 (5) e2021050049

Controlled human malaria infection—Maker and breaker of dogma
Jean-Marc Chavatte, Georges Snounou
| published 26 Apr 2021 PLOS Medicine
https://doi.org/10.1371/journal.pmed.1003591
Management of insecticides for use in disease vector control: Lessons from six countries in Asia and the Middle East
Henk van den Berg, Raman Velayudhan, Rajpal S. Yadav
Research Article | published 30 Apr 2021 PLOS Neglected Tropical Diseases
https://doi.org/10.1371/journal.pntd.0009358

Genomic and epidemiological characteristics of SARS-CoV-2 in Africa
Research Article | published 26 Apr 2021 PLOS Neglected Tropical Diseases
https://doi.org/10.1371/journal.pntd.0009335

PLoS One
http://www.plosone.org/
[Accessed 1 May 2021]
Risk communication during COVID-19: A descriptive study on familiarity with, adherence to and trust in the WHO preventive measures
Nirosha Elsem Varghese, Iryna Sabat, Sebastian Neumann-Böhme, Jonas Schreyögg, Tom Stargardt, Aleksandra Tobica, Job van Exel, Pedro Pita Barros, Werner Brouwer
Research Article | published 29 Apr 2021 PLOS ONE
https://doi.org/10.1371/journal.pone.0250872

Potential impact of introducing vaccines against COVID-19 under supply and uptake constraints in France: A modelling study
Laurent Coudeville, Ombeline Jollivet, Cedric Mahé, Sandra Chaves, Gabriela B. Gomez
Research Article | published 28 Apr 2021 PLOS ONE
https://doi.org/10.1371/journal.pone.0250797

Willingness to vaccinate against COVID-19 among Bangladeshi adults: Understanding the strategies to optimize vaccination coverage
Research Article | published 27 Apr 2021 PLOS ONE
https://doi.org/10.1371/journal.pone.0250495

PLoS Pathogens
http://journals.plos.org/plospathogens/
[Accessed 1 May 2021]
[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States of America
April 27, 2021; vol. 118 no. 17
https://www.pnas.org/content/118/17
Public Health Ethics
Volume 13, Issue 3, November 2020
http://phe.oxfordjournals.org/content/current
[Reviewed earlier]

Public Health Reports
Volume 136 Issue 2, March/April 2021
https://journals.sagepub.com/toc/phrg/136/2
[Reviewed earlier]

Qualitative Health Research
Volume 31 Issue 5, April 2021
http://qhr.sagepub.com/content/current
[Reviewed earlier]

Research Ethics
Volume 17 Issue 2, April 2021
http://journals.sagepub.com/toc/reab/current
[Reviewed earlier]

Reproductive Health
http://www.reproductive-health-journal.com/content
[Accessed 1 May 2021]
[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)
https://www.paho.org/journal/en
Selected Articles
28 Apr 2021
Leaving no one behind: a methodology for setting health inequality reduction targets for Sustainable Development Goal 3*
Original research | English |

Interaction among environmental and socioeconomic determinants of risk for cutaneous leishmaniasis in Latin America
Original research | Spanish |

Critical care medicine in the French Territories in the Americas: Current situation and prospects
Opinion and analysis | English |

Planning for health equity in the Americas: an analysis of national health plans
One key way that many governments around the world incorporate scientific research into policy-making is through cost-benefit analysis (CBA). But despite well-established practices for rigorous estimation of the pros and cons of policies, there is room to improve, particularly in characterizing difficult-to-measure benefits and the distribution of the costs and benefits across different segments of society. In this regard, announcements by US President Biden, if brought to fruition, could have far-reaching implications for how CBA is used in government decision-making. But such promising (and familiar) rhetoric is no guarantee of real progress, and the devil, as always, is in the details. These details are where the scientific community has an important role to play to improve the use of CBA and to hold the administration accountable.

In Depth
Relief and worry for immune-suppressed people
By Jennifer Couzin-Frankel
Science30 Apr 2021 : 443-444 Full Access
Early studies suggest COVID-19 vaccine protection varies by ailment and treatment.

Summary
Many millions of people worldwide have suppressed immune systems because of illness or medications, including those taken after an organ transplant, for an autoimmune disease, or to treat cancer—and a big question is how well COVID-19 vaccines work for them. In many, the vaccines do seem to maintain their potency. But in others—particularly organ transplant recipients and those taking specific immune-dampening medications—effectiveness is less assured or even absent. To learn more, researchers are
launching larger studies, seeking clarity for these patients and ways to help those in need, especially as their weakened immune systems make protection against COVID-19 all the more urgent.

**Science Translational Medicine**
28 April 2021  Vol 13, Issue 591  
[New issue; No digest content identified]

**Social Science & Medicine**
Volume 275  April 2021  
[No new digest content identified]

**Systematic Reviews**
[Accessed 1 May 2021]
[No new digest content identified]

**Theoretical Medicine and Bioethics**
Volume 41, issue 5-6, December 2020  
[Reviewed earlier]

**Travel Medicine and Infectious Diseases**
Volume 40  March–April 2021  
[Reviewed earlier]

**Tropical Medicine & International Health**
Volume 26, Issue 4  Pages: i-iv, 385-502  April 2021  
[Reviewed earlier]
A decade of rotavirus vaccination in Africa - Saving lives and changing the face of diarrhoeal diseases: Report of the 12th African Rotavirus Symposium
M. Jeffrey Mphahlele, Michelle J. Groome, Nicola A. Page, Niresh Bhagwandin, ... A. Duncan Steele
Pages 2319-2324

Are vaccines against COVID-19 tailored to the most vulnerable people?
Raffaele Antonelli Incalzi, Caterina Trevisan, Susanna Del Signore, Stefano Volpato, ... Anette Hylen Ranhoff
Pages 2325-2327

Safeguarding evidence-based decision making in the FDA for COVID-19 vaccines
Aris Angelis, Jonathan Darrow
Pages 2328-2330

Parents’ knowledge, beliefs, acceptance and uptake of the HPV vaccine in members of The Association of Southeast Asian Nations (ASEAN): A systematic review of quantitative and qualitative studies
Kurnia Eka Wijayanti, Heike Schütze, Catherine MacPhail, Annette Braunack-Mayer
Pages 2335-2343

Projecting the impact of a two-dose COVID-19 vaccination campaign in Ontario, Canada
Thomas N. Vilches, Kevin Zhang, Robert Van Exan, Joanne M. Langley, Seyed M. Moghadas
Pages 2360-2365

Joining the herd? U.S. public opinion and vaccination requirements across educational settings during the COVID-19 pandemic
Simon F. Haeder
Pages 2375-2385

Parental vaccine hesitancy and its association with adolescent HPV vaccination
Kimberly H. Nguyen, Tammy A. Santibanez, Shannon Stokley, Megan C. Lindley, ... James Singleton
Pages 2416-2423

Pro-equity immunization and health systems strengthening strategies in select Gavi-supported countries
Ibrahim Dadari, Ariel Higgins-Steele, Alyssa Sharkey, Danielle Charlet, ... Debra Jackson
**Research article  Full text access**
*The social experience of participation in a COVID-19 vaccine trial: Subjects’ motivations, others’ concerns, and insights for vaccine promotion*
Emily Wentzell, Ana-Monica Racila
Pages 2445-2451

**Research article  Full text access**
*U.S. public support for COVID-19 vaccine donation to low- and middle-income countries during the COVID-19 pandemic*
Jeanine P.D. Guidry, Paul B. Perrin, Linnea I. Laestadius, Emily K. Vraga, ... Kellie E. Carlyle
Pages 2452-2457

**Research article  Open access**
*NIH funding for vaccine readiness before the COVID-19 pandemic*
Anthony E. Kiszewski, Ekaterina Galkina Cleary, Matthew J. Jackson, Fred D. Ledley
Pages 2458-2466

**History of Vaccinology paper**
**Research article  Abstract only**
*A half-century of meningococcal vaccines*
Andrew W. Artenstein
Pages 2475-2478

**Vaccines — Open Access Journal**
http://www.mdpi.com/journal/vaccines
(Accessed 1 May 2021)

**Open Access  Article**
*Confidence, Acceptance and Willingness to Pay for the COVID-19 Vaccine among Migrants in Shanghai, China: A Cross-Sectional Study*
by Kaiyi Han et al
Vaccines 2021, 9(5), 443; https://doi.org/10.3390/vaccines9050443 (registering DOI) - 02 May 2021
Abstract
Understanding the public’s attitude towards COVID-19 vaccination and their acceptance could help facilitate the COVID-19 rollout. This study aimed to assess the acceptance and willingness to pay (WTP) for the COVID-19 vaccine among migrants in Shanghai, China. A cross-sectional study was conducted among [...]
**Value in Health**
Volume 24  Issue 5  p605-752
https://www.valueinhealthjournal.com/current

**THEMED SECTION: COVID-19**

**How Should the World Pay for a Coronavirus Disease (COVID-19) Vaccine?**
Adrian Towse, et al
Published online: February 18, 2021
p625-631
Open Access

**Quality-Adjusted Life-Year Losses Averted With Every COVID-19 Infection Prevented in the United States**
Anirban Basu, Varun J. Gandhay
Published online: March 08, 2021
p632-640

* * * * *

**Media/Policy Watch**
This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. *Media Watch* is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from *Journal Watch* above which scans the peer-reviewed journal ecology.

We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.

The sheer volume of vaccine and pandemic-related coverage is extraordinary. We will strive to present the most substantive analysis and commentary we encounter.

**The Atlantic**
http://www.theatlantic.com/magazine/
Accessed 1 May 2021
[No new, unique, relevant content]

**BBC**
http://www.bbc.co.uk/
Accessed 1 May 2021
**Covid-19: India’s vaccine shortage**
**The Economist**  
http://www.economist.com/  
Accessed 1 May 2021  

**Daily chart**  
**Vaccine diplomacy boosts Russia’s and China’s global standing**  
It is a way to reward old friends and win new ones  
Apr 29th 2021

---

**Financial Times**  
https://www.ft.com/  
Accessed 1 May 2021  

**Covid-19 vaccines**  
**Is there a ban on Covid vaccine exports in the US?**  
Very few jabs made in America have gone overseas even though there are no formal controls  

---

**Coronavirus pandemic**  
**Patchwork of vaccine passports complicates return of global travel**  
April 30, 2021  

**Coronavirus pandemic**  
**Indians vent fury as world’s richest cricket tournament plays on**  
The Indian Premier League has provoked outrage for playing through the country’s brutal Covid-19 wave, drawing accusations of “crass” conduct and diverting vital resources from fighting the public health emergency. Several players including Ravichandran Ashwin, India’s premier off-spinner, and
three Australians pulled out of the cricket tournament this week over concerns about India’s rising caseload.
April 30, 2021

Forbes
http://www.forbes.com/
Accessed 1 May 2021
**Fake Covid-19 Vaccination Record Cards Are A Growing Problem, Says FBI**
Templates and instructions to make such cards are appearing online. The FBI is warning that such activity could be breaking the law.
By Bruce Y. Lee Senior Contributor
May 1, 2021

Foreign Affairs
http://www.foreignaffairs.com/
Accessed 1 May 2021
**Snapshot** April 28, 2021
**A Country Gasping for Air**
Indians pay the price of government inaction as COVID-19 surges.
Mandakini Gahlot

Foreign Policy
http://foreignpolicy.com/
Accessed 1 May 2021
[No new, unique, relevant content]

New Yorker
http://www.newyorker.com/
Accessed 1 May 2021
[No new, unique, relevant content]

New York Times
http://www.nytimes.com/
Accessed 1 May 2021
**World**
**Adar Poonawalla, head of India’s vaccine giant, speaks from London of the enormous pressure he is under.**
The executive told The Times of London that he had arrived in Britain for “an extended time” just before travel restrictions would have blocked him. But he then tweeted he would return to India in days after business meetings.
By Sameer Yasir 1 May 2021

**World**
**India’s Covid crisis has tarnished Modi’s aura of political invulnerability.**
**World**

**Nepal runs out of hospital beds as India’s outbreak spills across the border.**

Health officials in the Himalayan nation warn of an “unmanageable” situation as infections reach levels not seen since last fall.

By Bhadra Sharma 1 May 2021

---

**World**

**Turkey braces for its strictest lockdown yet, as the virus surges and vaccinations lag.**

With an order about to take effect keeping people at home for three weeks except for essential errands and jobs, many Turks rushed to stock their pantries or flee crowded cities.

April 29

---

**Washington Post**

[https://www.washingtonpost.com/](https://www.washingtonpost.com/)

Accessed 1 May 2021

**Asia**

**India’s coronavirus surge creates vaccine supply turmoil far beyond its borders**

Adam Taylor · Apr 30, 2021

As coronavirus cases surged this month in India, the country that houses the world’s largest vaccine manufacturer, the government began to pause vaccine exports.

Shipments ground to a halt by mid-April. Now, with domestic need for vaccine in India overwhelming capacity and program extending to adults over 18 this weekend, it is not clear when India will begin exporting doses again.

The suspension of exports in April has contributed to a 90 million-dose shortfall for Covax, an international vaccine distribution effort, one of the group’s key backers said Friday. That number will only grow in May if restrictions are not lifted.

The limited supply would be a particularly big blow for low-income nations, many of which not only sought India-produced AstraZeneca through Covax but also pursued bilateral deals with Serum Institute of India, the Pune-based vaccine giant.

Arindam Bagchi, a spokesman for India’s Foreign Ministry, said Friday there was “no update” on when vaccine exports would resume...

---

**Think Tanks et al**

**Brookings**

[http://www.brookings.edu/](http://www.brookings.edu/)

Accessed 1 May 2021

[No new digest content identified]

**Center for Global Development**  [to 1 May 2021]

India Needs to Focus on Three Urgent Actions to Mitigate its COVID-19 Humanitarian Crisis

India’s second COVID-19 wave has been explosive, reaching world record totals of over 300,000 daily officially reported cases. The true number is likely to be much higher, with a large number of cases missed as indicated by the delays in testing and rapidly rising positivity rates - currently one in every four people tested are positive for COVID-19 across India. Leading models estimate that there could be over 1 million cases per day. The health service has collapsed, with queues of ambulances parked outside full hospitals, oxygen and drug shortages in multiple states, and life-saving non-COVID services interrupted.

Peter Baker et al.

Chatham House  [to 1 May 2021]
https://www.chathamhouse.org/
Accessed 1 May 2021

COVID-19: Tackling India’s second wave
Chatham House experts give insights into India’s current crisis, and lessons to be learned to better prepare for potential spikes or new waves of COVID-19.
Interview
28 April 2021

CSIS
https://www.csis.org/
Accessed 1 May 2021

Critical Questions
The COVAX Advance Market Commitment ‘One World Protected’ Investment Opportunity Launch
April 27, 2021
Katherine E. Bliss
Senior Fellow, Global Health Policy Center

Kaiser Family Foundation
https://www.kff.org/search/?post_type=press-release
Accessed 1 May 2021

What Could the U.S. Do to Help Improve Global COVID-19 Vaccine Equity?
As India and other countries continue to grapple with major COVID-19 outbreaks even as cases decline in this country, there is increasing attention to the global role that could be played by the U.S. government. This is particularly the case now that the U.S. will soon have enough COVID-19 vaccine...

World Economic Forum  [to 1 May 2021]
https://agenda.weforum.org/news/
Media
Public Supports COVID-19 Vaccine Certificate for International Travel, Not Everyday Activities

* The global public widely supports requiring vaccine certificates for international travel and accessing large venues, however, support is divided when it comes to measures around daily life
* Only half agree vaccine certificates should be required for shops, restaurants, and offices, with a large majority in South Asia and Latin America supporting such measures
* Health expert calls for international regulations to adapt and for universal access to vaccines to ensure two classes of global citizens are not created
* Watch the Forum’s panel on ensuring vaccine equity; read the highlights blog
* View the survey details

---

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global, which is solely responsible for its content, and is an open access publication, subject to the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/3.0/). Copyright is retained by CVEP.

CVEP is a program of the GE2P2 Global Foundation – whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, PATH, and industry resource members Janssen/J&J, Pfizer and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.